supp.fit

Calcium and Vitamin D: study protocols

762 study groups took Calcium together with Vitamin D. These are the doses the studies gave. They are not a recommendation.

Calcium: what the research found →

Dose per serving from research: Calcium

756 study groups in 490 studies say how much Calcium participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 49% of 756 study groups.

Daily doseStudy groups
250 mg or less
18
250 mg to 500 mg
214
500 mg to 1 g
372
1 g to 2.5 g
137
over 2.5 g
15

Dose per serving from research: Vitamin D

489 study groups in 320 studies say how much Vitamin D participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 IU to 1,000 IU, 41% of 489 study groups.

Daily doseStudy groups
100 IU or less
4
100 IU to 250 IU
49
250 IU to 500 IU
154
500 IU to 1,000 IU
200
1,000 IU to 2,500 IU
39
2,500 IU to 5,000 IU
26
over 5,000 IU
17

Commonly used together

117 of 762 study groups took Calcium and Vitamin D with something else. Shown: what 3 or more different studies gave. The 10 most common of 15.

What was given together, not what works together.

Taken withStudy groups
Vitamin K
18
Zinc
13
Vitamin B12
11
Multivitamin
10
Folic Acid
9
Magnesium
8
Iron
6
Vitamin B6
6
Soy Isoflavones
4
Vitamin E
4

762 study groups

Study
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements
2011 · CaD group · Postmenopausal women aged 50–79 years
1 g400 IU7 years18,176
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study
2013 · Calcium plus vitamin D (CaD) group · Postmenopausal women aged 50–79 years
1 g400 IU7 years18,176
A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast
2021 · calcium plus vitamin D · Postmenopausal women aged 50–79 years at enrollment
1 g400 IU2592 days18,176
Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation
2017 · active treatment · older women; median age 63 years
1 g400 IU7 years18,141
Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative
2015 · intervention group · Postmenopausal women aged 50–79 years, free of heart failure at baseline, with and without pre-existing cardiovascular risk conditions
1 g400 IU2577 days18,023
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study
2004 · Calcium and Vitamin D Program · Community-dwelling residents aged 66 years and older
1 g400 IU3 years4,957
Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial
2017 · vitamin D3 + calcium group · Healthy postmenopausal women aged 55 years or older
1.5 g2,000 IU1461 days1,156
Zoledronic acid and clinical fractures and mortality after hip fracture
2007 · zoledronic acid group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture
1 g800 IU1826 days1,065
Zoledronic acid and clinical fractures and mortality after hip fracture
2007 · placebo group · Men and women aged 50 years or older after surgical repair of a recent minimal-trauma hip fracture
1 g800 IU1826 days1,062
Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study
2015 · supplement group — women · Women aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China
324 mg20 mcg6 years927
Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study
2015 · supplement group — men · Men aged 40–69 with esophageal squamous dysplasia (ESD) in Linxian, China
324 mg20 mcg6 years726
Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial
2020 · intervention · Patients with confirmed benign paroxysmal positional vertigo (BPPV); supplementation was given when serum vitamin D was below 20 ng/mL
1 g800 IU1 year518
Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial
2019 · calcium and vitamin D · Adults aged 45–75 with at least one adenomatous polyp detected and removed within the preceding 4 months
1.2 g1,000 IU5 years421
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 200-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
1 g400 IU5 years287
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · Placebo group · Postmenopausal women with established osteoporosis
1 g400 IU5 years270
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study
2009 · Risedronate group · Men with primary or secondary osteoporosis
1 g800 IU2 years158
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Placebo (Ca-D group) · Postmenopausal women with osteoporosis and vertebral fractures
1 g800 IU2 years146
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women
800 mg0.5 mcg1 year99
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 71 years, predominantly women
800 mg800 IU1 year98
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · P-A VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 72 years, predominantly women
800 mg0.5 mcg1 year98
Comprehensive Interventions Including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients
2021 · P-NA VitD group · Adults over 60 years with osteoporosis (BMD at or below −2.5), recurrent osteoporosis-related pain; mean age about 70 years, predominantly women
800 mg800 IU1 year97
The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial
2020 · Vitamin D with calcium · Overweight subfertile women with PCOS undergoing ovulation induction
2.5 g——93
Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery
2018 · Control group · Adults undergoing total or completion thyroidectomy with at least one well-perfused parathyroid gland identified by indocyanine green angiography; men and women; thyroid disease requiring surgery
2 g1,600 IU15 days73
Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial
2023 · Perioperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy
4.5 g1 mcg17 days68
Perioperative versus postoperative calcium and vitamin D supplementation to prevent symptomatic hypocalcemia after total thyroidectomy: a randomized placebo controlled trial
2023 · Postoperative supplementation group · Adults older than 18 years undergoing total or completion thyroidectomy
4.5 g1 mcg2 weeks66
Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial
2003 · Cal+D-group · Elderly women aged 63–99 years in long-stay geriatric care
1.2 g800 IU12 weeks62
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study
2020 · experiment group · Men and women aged 80–93 years with osteopenia living independently
600 mg125 IU548 days62
Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study
2020 · control group · Men and women aged 80–93 years with osteopenia living independently
600 mg125 IU548 days61
Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection
2009 · Group A · Patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection; age and sex not specified
3 g1 mg—49
Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy
2006 · oral calcium/vitamin D group · patients who underwent total thyroidectomy; age and sex not specified
3 g1 g2 weeks45
Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial
2021 · Control group · Patients undergoing total thyroidectomy; age and sex not reported
4.5 g0.5 mcg—44
[Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia]
2014 · VD group · Men with idiopathic oligoasthenozoospermia
600 mg200 IU90 days43
Does Preoperative Calcium and Calcitriol Decrease Rates of Post-Thyroidectomy Hypocalcemia? A Randomized Clinical Trial
2021 · Intervention group · Patients undergoing total thyroidectomy; age and sex not reported
4.5 g0.5 mcg—38
Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?
2006 · Vitamin D plus calcium · Institutionalized women aged 65–97
1.2 g800 IU90 days33
Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis
2012 · Cholecalciferol group · Postmenopausal women with osteoporosis
1 g300,800 IU7 days30
Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis
2012 · Placebo group with shared supplementation · Postmenopausal women with osteoporosis
1 g800 IU7 days30
Calcium plus vitamin D supplementation affects pregnancy outcomes in gestational diabetes: randomized, double-blind, placebo-controlled trial
2016 · Ca+vitamin D group · Pregnant women with gestational diabetes mellitus (GDM) in Arak, Iran
1 g—6 weeks30
The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial
2022 · Experimental group · Adults aged 20–80 undergoing elective lumbar spinal fusion for spinal stenosis or degenerative spondylolisthesis
600 mg800 IU90 days21
A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children
1999 · combination-therapy group · Nigerian children with nutritional rickets; median age 46 months
1 g—24 weeks—
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · risedronate 2.5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
1 g500 IU2 years—
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · risedronate 5 mg/day group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
1 g500 IU3 years—
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
2000 · placebo group · postmenopausal women with two or more prevalent vertebral fractures and established osteoporosis
1 g500 IU3 years—
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 100-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
1 g400 IU5 years—
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
2000 · 400-IU salmon calcitonin group · Postmenopausal women with established osteoporosis
1 g400 IU5 years—
Varying role of vitamin D deficiency in the etiology of rickets in young children vs. adolescents in northern India
2003 · Calcium with vitamin D · Children with rickets and adolescents with rickets/osteomalacia
1 g—23 weeks—
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial
2005 · risedronate group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency
1.2 g1,000 IU548 days—
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial
2005 · control group · Elderly women with Alzheimer disease and baseline 25-hydroxyvitamin D deficiency
1.2 g1,000 IU548 days—
Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial
2005 · Vitamin D supplementation group · Older residents of residential care, mean age 83.4 years, with serum 25-hydroxyvitamin D levels of 25–90 nmol/L
600 mg—2 years—
Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial
2006 · cholecalciferol-calcium · Ambulatory, community-dwelling men and women aged 65 years or older
500 mg700 IU3 years—
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial
2007 · PTH group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine
700 mg—548 days—
Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial
2007 · Ca + D · Healthy postmenopausal women aged over 55 years
1.4 g1,100 IU4 years—
Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial
2008 · calcium plus vitamin-D supplementation · Women in the Women's Health Initiative; age and specific health conditions are not stated in the abstract
1 g400 IU——
Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women
2008 · ergocalciferol group · Community-dwelling women aged 70–90 with serum 25-hydroxyvitamin D below 24.0 ng/mL and a history of falling in the previous year
1 g1,000 IU1 year—
Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women
2008 · vitamin D3 plus calcium · Community-dwelling, healthy ambulatory men and women aged 65 years or older
500 mg700 IU3 years—
Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits
2008 · calcium and vitamin D group · female Navy recruits undergoing basic training
2 g800 IU8 weeks—
Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals
2009 · calcium plus vitamin D · Community-dwelling women and men, mean age 77 years, with serum 25-hydroxyvitamin D below 78 nmol/l
1 g800 IU1 year—
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study
2009 · Control group without previous vertebral fractures · Men with primary or secondary osteoporosis without previous vertebral fractures
1.2 g800 IU2 years—
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial
2009 · CaD supplementation · Postmenopausal women aged 51–82 years
1 g400 IU2557 days—
Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial
2011 · CaD (calcium plus vitamin D) · Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative calcium/vitamin D trial
1 g400 IU7 years—
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set
2011 · Calcium and vitamin D (CaD) · Community-dwelling postmenopausal women
1 g400 IU2557 days—
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy
2014 · Active CaD + active hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis
1 g400 IU2628 days—
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy
2014 · Active CaD + placebo hormone therapy · Postmenopausal women aged 50–79; not selected for low bone density or osteoporosis
1 g400 IU2628 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 1000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
200 mg1,000 IU90 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 2000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
200 mg2,000 IU90 days—
Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D
2014 · 4000 IU vitamin D group · Black or African-American adults aged 30–80 years in a healthy community-based population; the reported safety analysis included participants taking HCTZ
200 mg4,000 IU90 days—
The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial
2015 · calcium and vitamin D group · Postmenopausal women aged 50–79 years
1 g400 IU7 years—
Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials
2017 · Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause
1 g400 IU——
Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women's Health Initiative Clinical Trials
2017 · HT + Ca/D intervention · Postmenopausal women aged 50–79 with an intact uterus, included in the analytical sample by self-reported age of natural menopause
1 g400 IU——
Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial
2017 · Vitamin D3 plus calcium · Adults aged 45–75 with at least one large-bowel adenoma removed before enrollment
1.2 g1,000 IU1376 days—
The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk
2017 · calcium plus vitamin D group · White postmenopausal women
1 g400 IU339 weeks—
Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease
2019 · CaD-supplement group · Postmenopausal women in the Women's Health Initiative who entered the calcium and vitamin D trial after one year in a menopausal hormone therapy trial
1 g400 IU2264 days—
Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial
2020 · Vitamin D3 plus calcium carbonate · Men and women aged 45–75 recently diagnosed with a colorectal adenoma
1.2 g1,000 IU5 years—
Impact of Common Vitamin D-Binding Protein Isoforms on Supplemental Vitamin D3 and/or Calcium Effects on Colorectal Adenoma Recurrence Risk: A Secondary Analysis of a Randomized Clinical Trial
2023 · Vitamin D3 and calcium · Adults with a recently diagnosed colorectal adenoma and no remaining polyps after complete colonoscopy; the analyzed subgroup consisted of non-Hispanic White participants
1.2 g1,000 IU5 years—
Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial
2024 · CaD · Postmenopausal women with no history of breast or colorectal cancer
1 g400 IU7 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Sodium fluoride · Postmenopausal women with osteoporosis and vertebral fractures
1 g800 IU2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 200 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
1 g800 IU2 years—
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy
1998 · Monofluorophosphate, 150 mg/day · Postmenopausal women with osteoporosis and vertebral fractures
1 g800 IU2 years—
Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial
2017 · calcium carbonate + calcitriol · Patients with non-alcoholic fatty liver disease (NAFLD) following an energy-restricted weight-loss program; age and sex not stated
500 mg25 mcg12 weeks37
Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake
2005 · WL NL-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss
400 mg400 IU180 days22
Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake
2005 · WM NL-Ca · Overweight postmenopausal women aged 50–75 assigned to weight maintenance
400 mg400 IU180 days18
Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative
2011 · CaD group · Postmenopausal women aged 50–79 years
1 g—5 years1,179
Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women
2017 · group C · Postmenopausal women at high risk of osteoporosis
600 mg—2 years139
Effects of Enhanced Exercise and Combined Vitamin D and Calcium Supplementation on Muscle Strength and Fracture Risk in Postmenopausal Chinese Women
2017 · group D · Postmenopausal women at high risk of osteoporosis
600 mg0.25 mcg2 years131
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
2016 · Active · Adults aged 65 years or older who had undergone hip fracture surgery; men and women with a recent surgically repaired hip fracture
500 mg800 IU26 weeks111
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q6M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
600 mg400 IU1 year85
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q2M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
600 mg400 IU1 year85
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · denosumab 60 mg Q3M · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
600 mg400 IU1 year82
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial
2017 · Placebo arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61
1.2 g600 IU24 weeks80
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial
2017 · Vitamin D3 arm · Women with stage I–III breast cancer starting adjuvant letrozole, with 25(OH)D level ≤40 ng/ml; median age 61
1.2 g4,886 IU24 weeks80
High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women
2013 · aquatic exercise group (AEG) · Postmenopausal women, mean age 58.8 years
500 mg1,000 IU24 weeks64
Effects of vitamin D and/or calcium intervention on sleep quality in individuals with prediabetes: a post hoc analysis of a randomized controlled trial
2024 · vitamin D + calcium group · Chinese individuals with prediabetes; age and sex not specified
500 mg1,600 IU24 weeks53
Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial
2018 · Alfacalcidol group · Indonesian older women with handgrip strength ≤22 kg
500 mg0.5 mcg90 days47
High-intensity aquatic exercises (HydrOS) improve physical function and reduce falls among postmenopausal women
2013 · control group (CG) · Postmenopausal women, mean age 58.8 years
500 mg1,000 IU24 weeks44
Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial
2014 · Ca+D group · Children older than 1 year with active calcium-deficiency rickets
1.88 g—24 weeks44
A Nutritionally Complete Oral Nutritional Supplement Powder Improved Nutritional Outcomes in Free-Living Adults at Risk of Malnutrition: A Randomized Controlled Trial
2022 · nutrition supplement (intervention group) · Chinese men and women aged 18 years or older, all classified as at risk of malnutrition; mean age 66.5 years, range 41–89
400 mg8 mcg12 weeks44
Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV
2020 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy
1 g1,000 IU1 year41
Effect of vitamin D(3) and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV
2020 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 living with HIV, with serum 25-OHD of 10–32 ng/ml and stable antiretroviral therapy
1 g3,000 IU1 year41
Changes in body composition following a dietary and lifestyle intervention trial: the postmenopausal health study
2009 · dietary intervention group (DG) · Healthy postmenopausal women
1.2 g7.5 mcg1 year39
Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial
2014 · combined calcium and vitamin D treatment · Multi-ethnic men and women aged 18 years or older, vitamin D-deficient and at risk of type 2 diabetes; BMI 25–40 kg/m²
1.2 g2,000 IU26 weeks35
A randomized controlled trial of high dose vitamin D3 in patients with heart failure
2013 · Vitamin D3 group · Adults aged 50 years or older with heart failure (NYHA class II–IV) and serum 25OHD ≤37.5 ng/ml
800 mg7,143 IU26 weeks32
Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial
2015 · calcium plus vitamin D supplementation · Brazilian adolescent mothers consuming low-calcium diets, from 26 weeks of gestation until parturition
600 mg200 IU—30
Calcium plus vitamin D supplementation during pregnancy reduces postpartum fat mass in adolescents: A randomized trial
2023 · calcium plus vitamin D supplement · Brazilian pregnant adolescents aged 14–19 years with habitually low calcium intake
600 mg——30
The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study
2021 · control group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty
300 mg—90 days29
The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study
2021 · monitoring group · Postmenopausal women aged 55–75 with osteoporosis and osteoarthritis undergoing total knee arthroplasty
300 mg—214 days28
The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial
2022 · Vitamin D3 + calcium carbonate · Women with postpartum depression and a PPD score >12
500 mg—8 weeks27
Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial
2013 · calcium+D group · Generally healthy overweight or obese college students aged 18–25 years with daily calcium intake below 600 mg; predominantly female
600 mg125 IU12 weeks26
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study
2009 · Group 1 · Infertile women with polycystic ovary syndrome (PCOS); age not stated
1 g400 IU90 days20
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study
2009 · Group 2 · Infertile women with polycystic ovary syndrome (PCOS); age not stated
1 g400 IU90 days20
Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial
2010 · Cholecalciferol and calcium supplementation · Healthy adults with hypovitaminosis D; mean age 31.5 years; 24 men and 16 women across both groups
1 g—26 weeks20
Effects of Vitamin D and Calcium Fortified Yogurts on Gait, Cognitive Performances, and Serum 25-Hydroxyvitamin D Concentrations in Older Community-Dwelling Females: Results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) Randomized Controlled Trial
2019 · intervention group (fortified yogurt) · Females aged 65 years or older with hypovitaminosis D (serum 25OHD <75 nmol/L), living independently at home or in an autonomous residence
800 mg400 IU90 days20
The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal women
2022 · 500 ml semi-skimmed milk with added cholecalciferol · Postmenopausal women aged 60–80 years with vitamin D insufficiency at screening
619 mg200 mcg1 day20
Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study
2012 · Group B (calcium and calcitriol; PTH <5) · Adults aged 18–82 undergoing completion or total thyroidectomy, with POD1 PTH <5
3 g1 mcg15 days7
Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy?
2002 · group C · Patients who underwent total thyroidectomy
3 g1 mg26 weeks—
Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects
2006 · resistance training plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects
800 mg400 IU270 days—
Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects
2006 · control (no resistance training) plus vitamin D and calcium · Adults aged 70 years or older with 25-hydroxyvitamin D levels of 16 ng/mL or less; described as healthy elderly subjects
800 mg400 IU270 days—
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
2007 · RE+ (reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture
500 mg400 IU1 year—
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
2007 · RE− (no reinforcement) · Postmenopausal women aged 65–80 with osteoporosis or a low-trauma fracture
500 mg400 IU1 year—
Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain
2007 · calcium plus cholecalciferol · Postmenopausal women aged 50 to 79 years
1 g400 IU7 years—
Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial
2009 · active treatment · Postmenopausal women aged 50–79 years
1 g400 IU——
Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control
2009 · calcium+D supplementation · Overweight or obese women, mean age 43 years, with daily calcium intake below 800 mg
1.2 g10 mcg15 weeks—
A comparison between the efficacy of dydrogesterone and calcium plus vitamin D in improving women's general health
2010 · calcium plus vitamin D · Young women who were students at Shiraz University
1 g400 mg——
A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency
2010 · Vitamin D group · Women aged 70 to 90 with vitamin D insufficiency, living in the community
1 g1,000 IU1 year—
A pilot randomized controlled trial of oral calcium and vitamin D supplementation using fortified laddoos in underprivileged Indian toddlers
2011 · study group · Underprivileged toddlers, mean age 2.7 years; most were hypocalcaemic and vitamin D deficient
405 mg—1 year—
Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial
2011 · Vitamin D and calcium group · Adults at high risk of type 2 diabetes; mean age 57 years
800 mg2,000 IU16 weeks—
Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults
2012 · Calcium and vitamin D-fortified regular orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated
1.05 g300 IU16 weeks—
Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults
2012 · Calcium and vitamin D-fortified lite orange juice · Overweight and obese adults; mean age 40.0 ± 12.9 years; sex not stated
1.05 g300 IU16 weeks—
School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls
2012 · Ca-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India
500 mg—1 year—
Skeletal muscle strength in young Asian Indian females after vitamin D and calcium supplementation: a double-blind randomized controlled clinical trial
2012 · cholecalciferol/calcium · young adult Asian Indian females with vitamin D deficiency; mean age 21.7 years
1 g—26 weeks—
Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial
2013 · vitamin D(3) plus calcium · Adults aged 45–75 in good health, with a history of colorectal adenoma and serum 25-hydroxyvitamin D ≥12 ng/mL
1.2 g1,000 IU——
Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls
2014 · Ca+D group (C2) · Underprivileged premenarchal girls aged 8–12 years
500 mg—1 year—
Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial
2014 · control group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency
200 mg—8 weeks—
Effects of Calcium Plus Vitamin D Supplementation on Anthropometric Measurements and Blood Pressure in Vitamin D Insufficient People with Type 2 Diabetes: A Randomized Controlled Clinical Trial
2015 · 50,000 IU/wk vitamin D3 plus 1000 mg/d calcium · People with type 2 diabetes and vitamin D insufficiency
1 g7,143 IU8 weeks—
A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods
2015 · VDCa group · Adult male and female volunteers aged 50 years or older
1 g800 IU26 weeks—
Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial
2017 · calcium-vitamin D group · Women students with moderate or severe primary dysmenorrhea
1 g5,000 IU——
Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial
2016 · CaD group · Postmenopausal women aged 50–79, generally healthy
1 g400 IU8 years—
High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women
2017 · high dose group · Postmenopausal women with low bone mineral density
1 g—1 year—
High dose vitamin D may improve lower urinary tract symptoms in postmenopausal women
2017 · standard dose group · Postmenopausal women with low bone mineral density
1 g800 IU1 year—
Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial
2020 · Group 1—fortified milk and early therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis
1 g1,000 IU——
Vitamin D and Calcium Milk Fortification in Pregnant Women with Periodontitis: A Feasibility Trial
2020 · Group 3—fortified milk and late therapy · Pregnant women aged 18 years or older with low-risk pregnancy and periodontitis
1 g1,000 IU——
Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients
2021 · calcium carbonate group · Alcohol-dependent patients undergoing inpatient alcohol-withdrawal treatment; age and sex not specified
800 mg5 mcg2 weeks—
Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile
2021 · Fortified sachet and powdered milk plus periodontal treatment during pregnancy (early PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation
1 g1,000 IU——
Exploratory Efficacy of Calcium-Vitamin D Milk Fortification and Periodontal Therapy on Maternal Oral Health and Metabolic and Inflammatory Profile
2021 · Fortified sachet and powdered milk plus periodontal treatment after delivery (late PT + fortification) · Adult pregnant women with periodontitis; age over 18 years, enrolled by up to 20 weeks’ gestation
1 g1,000 IU——
Daily intake of yogurt drink fortified either with vitamin D alone or in combination with added calcium causes a thyroid-independent increase of resting metabolic rate in adults with type 2 diabetes: a randomized, double-blind, clinical trial
2021 · Ca-D-fortified yogurt drink (CDY) · Adults with type 2 diabetes
500 mg1,000 IU12 weeks—
Effects of vitamin D on sex steroids, luteinizing hormone, and testosterone to luteinizing hormone ratio in 307 infertile men
2024 · active group · infertile men
500 mg301,400 IU150 days—
Effect of Calcium and Vitamin D Supplementation (Dairy vs. Pharmacological) on Bone Health of Underprivileged Indian Children and Youth with Type-1 Diabetes: A Randomized Controlled Trial
2024 · Calcium supplement (group B) · Underprivileged Indian children and youth aged 5–23 years with type-1 diabetes mellitus; both sexes
500 mg1,000 IU1 year—
Alcohol use disorder and muscle weakness: Original study of the effect of vitamin D supplementation in ambulatory participants with alcohol use disorder
2024 · CAU (care as usual) · Community-dwelling adults with alcohol use disorder; ages and sex by arm not reported. The reported outcome subgroup had vitamin D concentrations below 50 nmol/L.
500 mg800 IU1 year—
Effect of cholecalciferol supplementation on hand grip strength, walking speed, and expression of vitamin D receptor, interleukin-6, and insulin-like growth factor-1 in monocyte in pre-frail older adults: A randomized double-blind placebo-controlled trial
2024 · cholecalciferol group · pre-frail older adults
500 mg4,000 IU12 weeks—
Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial
2025 · D12 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL
400 mg4,286 IU12 weeks—
Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A Prospective Double-Blind Two-Phase Randomized Controlled Clinical Trial
2025 · D24 · Premenopausal women aged 18 or older with PCOS and serum 25(OH)D of 10–30 ng/mL
400 mg4,286 IU24 weeks—
Phosphate concentration is exceptionally high in seminal fluid and is linked with semen quality but not influenced by vitamin D and calcium supplementation
2025 · vitamin D and calcium supplementation · infertile men; age range and sex beyond male not specified
500 mg—150 days—
Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field
2025 · Group A (PEMF and rhPTH) · Postmenopausal women with osteoporosis; mean age 65.21 years
600 mg—548 days115
Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field
2025 · Group B (rhPTH) · Postmenopausal women with osteoporosis; mean age 65.23 years
600 mg—548 days113
Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field
2025 · Group C (PEMF) · Postmenopausal women with osteoporosis; mean age 65.37 years
600 mg—548 days108
A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery
2022 · Intervention group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy
1 g—1 year71
A smartphone application to improve adherence to vitamin and mineral supplementation after bariatric surgery
2022 · Control group · Adults aged over 18 to 60 years undergoing gastric bypass or sleeve gastrectomy
1 g—1 year69
Leucine-Enriched Protein Supplementation Increases Lean Body Mass in Healthy Korean Adults Aged 50 Years and Older: A Randomized, Double-Blind, Placebo-Controlled Trial
2020 · protein mixture powder (intervention group) · Healthy Korean adults aged 50–80 years, men and women, without sarcopenia
600 mg1,600 IU12 weeks54
The effect of 12-weeks Nutritional supplementation on Nutritional Intake and Status among Indonesian Older Outpatients with Malnutrition Risk, the Prolansia study: a randomized controlled trial
2025 · intervention group (standard care plus NDD) · Men and women aged 60 years and older with malnutrition or at risk of malnutrition, attending outpatient clinics in Indonesia
500 mg800 IU12 weeks54
Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause
2006 · ES (Estromineral serena) · Symptomatic menopausal women with sleep or mood alterations
141 mg—24 weeks44
Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial
2024 · combo group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment
800 mg38 mcg16 weeks36
Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial
2024 · training group · Men aged 70 years or older with low-normal to low testosterone and mobility impairment
800 mg38 mcg16 weeks36
Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial
2018 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS); age not reported
800 mg400 IU12 weeks30
A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial
2017 · SUPP (multi-ingredient nutritional supplement) · Healthy men aged 60 years or older
800 mg1,000 IU20 weeks25
A prospective randomized comparative trial evaluating postoperative nutritional intervention in patients with oral cancer
2022 · Intervention group · Adults with oral cancer after surgery; ages 18 and older, both sexes
1 g2,857 IU26 weeks22
Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management
2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor
416 mg1,000 IU12 weeks16
The Effect of a Multi-ingredient Supplement on Resistance Training-induced Adaptations
2021 · SUPP group · Healthy young adults, male and female, mean age 22 ± 2 years, undertaking resistance exercise training
600 mg2,000 IU10 weeks13
School-based calcium-vitamin D with micronutrient supplementation enhances bone mass in underprivileged Indian premenarchal girls
2012 · Ca+MZ-group · Premenarchal girls aged 8–12 years from low-income groups in Pune, India
500 mg—1 year—
Effect of micronutrient supplementation on height velocity of underprivileged girls in comparison with un-supplemented healthy controls
2014 · Ca+MZn+D group (C1) · Underprivileged premenarchal girls aged 8–12 years
500 mg—1 year—
Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: a randomized clinical trial
2014 · intervention group · Pregnant women at 24–26 weeks of gestation with vitamin D deficiency or insufficiency
200 mg—8 weeks—
Vitamin D insufficiency does not affect bone mineral density response to raloxifene
2005 · All participants: daily calcium and cholecalciferol supplementation · Postmenopausal women participating in the Multiple Outcomes of Raloxifene Evaluation trial
500 mg—213 days7,522
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective
2006 · placebo group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older
1 g—578 days544
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective
2006 · teriparatide group with daily supplements · Postmenopausal women aged 42–86 with osteoporosis; age-subgroup analysis included women younger than 75 and women 75 and older
1 g—578 days541
Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
2020 · placebo-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated
600 mg400 IU2 years481
Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
2020 · denosumab-treated subjects · People with primary osteoporosis; baseline vitamin D status included deficient, insufficient, and sufficient groups; age and sex not stated
600 mg400 IU2 years475
Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial
2014 · CaD · Postmenopausal women aged 50–79 years from the general community
1 g400 IU—291
Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS)
2010 · supplementation group · Ambulatory postmenopausal women aged 66 to 71 years
1 g800 IU3 years287
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
2007 · alendronate 10 mg/elemental calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day
1 g400 IU2 years280
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
2012 · 1 mg daily minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis
610 mg400 IU1 year234
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
2012 · 30 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis
610 mg400 IU1 year229
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
2012 · 50 mg monthly minodronate group · Men and postmenopausal women aged 51–89 with involutional osteoporosis
610 mg400 IU1 year229
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study
2012 · open-label extension · Men with osteoporosis; age range not reported
1 g—2 years218
The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease
2012 · calcium-vitamin D3 fixed combination group (Ca-D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency
1.2 g800 IU2 years206
The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease
2012 · separate calcium and vitamin D3 supplements group (Ca + D3) · Elderly institutionalized women, mean age 85 years, with moderate chronic kidney disease and severe vitamin D deficiency
1.2 g800 IU2 years189
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
2016 · TPTD group · Postmenopausal women and men with osteoporosis; age range not stated
610 mg400 IU72 weeks153
No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year
2010 · DD group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese
500 mg—1 year147
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
2007 · alendronate-placebo/calcium 1000 mg · Healthy postmenopausal women with low bone mineral density and dietary calcium intake ≥800 mg/day
1 g400 IU2 years140
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
2016 · Placebo group · Postmenopausal women and men with osteoporosis; age range not stated
610 mg400 IU72 weeks137
No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year
2010 · DP group · Men and women aged 21–70 with BMI 28.0–47.0 kg/m² who were overweight or obese
500 mg—1 year132
Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
2006 · Placebo subcutaneous plus HRT · Postmenopausal women with low bone mass or osteoporosis
1 g—60 weeks125
Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy
2006 · Teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT) · Postmenopausal women with low bone mass or osteoporosis
1 g—60 weeks122
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
2006 · letrozole · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine
500 mg—2 years122
Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial
2014 · Group A (alfacalcidol) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis
500 mg0.5 mcg1 year118
Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis
2015 · ALN + VitD group · Japanese men and women aged 60–90 with primary osteoporosis or osteopenia and at least one vertebral fracture
610 mg400 IU48 weeks109
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
2018 · Placebo group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days
162 mg—48 weeks105
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
2006 · placebo · Postmenopausal women with primary breast cancer who completed at least 5 years of adjuvant tamoxifen and had baseline BMD T score of at least 2.0 in either the hip or L2–4 spine
500 mg—2 years104
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis
2004 · group A · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica
500 mg1 mcg3 years103
A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis
2006 · Calcium group · Children and adolescents aged 6–18 years with juvenile rheumatoid arthritis who had not taken corticosteroids for at least 3 months
1 g400 IU2 years103
[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis]
2004 · RLX group · Chinese postmenopausal women with osteoporosis
500 mg—1 year102
[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis]
2004 · placebo group · Chinese postmenopausal women with osteoporosis
500 mg—1 year102
Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis
2004 · group B · Adults with established glucocorticoid-induced osteoporosis receiving long-term glucocorticoid therapy, with or without vertebral fractures; underlying conditions included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica
500 mg1,000 IU3 years101
Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study
2025 · All patients · Patients aged 18–60 years with early active rheumatoid arthritis and no earlier use of disease-modifying anti-rheumatic drugs
1 g800 IU—99
Formula Milk Supplementation and Bone Acquisition in 4-6 Years Chinese Children: A 12-Month Cluster-Randomized Controlled Trial
2023 · formula milk group · Healthy Chinese children aged 4–6 years in rural Northwest China who were willing to drink milk but consumed little for economic reasons
720 mg4.5 mcg1 year96
Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation
2003 · supplementation · Ambulatory elderly women, mean age 75 years, with vitamin D insufficiency
1 g800 IU1 year95
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial
2015 · VitD/Cal group · HIV-infected adults initiating their first ART regimen with EFV/FTC/TDF
1 g4,000 IU48 weeks81
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis
2010 · Strontium ranelate group · Men with primary osteoporosis
1.2 g800 IU1 year76
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis
2010 · Alendronate group · Men with primary osteoporosis
1.2 g800 IU1 year76
Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women
2001 · vitamin D(3) and calcium group · Elderly women with 25-hydroxycholecalciferol below 50 nmol/L; mean age 74 years
1.2 g800 IU8 weeks74
Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis
2006 · vitamin D plus calcium group · Postmenopausal Caucasian patients with osteoporosis and normal vitamin D serum levels
1 g880 IU547 days72
Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up
2015 · milk powder supplementation group · Healthy postmenopausal women
900 mg800 IU2 years69
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
2014 · Aquatic Exercise Group (AEG) · Postmenopausal women, mean age 58.8 ± 6.4 years
500 mg1,000 IU24 weeks64
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group B · Patients with Crohn's disease and reduced BMD (T-score < -1)
800 mg1,000 IU1278 days62
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium
2003 · simple vitamin D (ergocalciferol) plus calcium carbonate · Females and males commencing or already taking glucocorticoids
600 mg4,286 IU2 years61
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
2012 · 500 mg calcium with 400 international unis (iu) vitamin D daily · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0)
500 mg400 IU1 year59
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
2012 · 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d · Adults with β-thalassaemia and osteoporosis (BMD Z scores ≤-2·0)
500 mg400 IU1 year59
A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study
2006 · calcitonin group · Postmenopausal Asian women with osteoporosis
500 mg—26 weeks57
Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients
2021 · bazedoxifene group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids
1.2 g800 IU56 weeks57
Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients
2021 · control group · Postmenopausal women aged 45 years or older with rheumatoid arthritis and osteopenia, receiving low-dose glucocorticoids
1.2 g800 IU56 weeks57
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca6D group · Healthy Chinese adolescents aged 11.9–15.2 years
600 mg400 IU548 days56
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
2006 · Control group · Patients with orthotopic liver transplantation
1 g0.5 mcg2 years54
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group C · Patients with Crohn's disease and reduced BMD (T-score < -1)
800 mg1,000 IU1278 days54
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca9D group · Healthy Chinese adolescents aged 11.9–15.2 years
900 mg400 IU548 days54
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients
2008 · experiment I group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified
4.5 g0.25 mcg1 year50
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients
2008 · experiment II group · Patients on maintenance dialysis with chronic renal failure, at risk of osteoporosis; age and sex not specified
4.5 g0.25 mcg1 year50
Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis
2020 · Arm A (TDF/FTC + Oskept) · Young men who have sex with men and young transgender women aged 15–24 years initiating PrEP
1.2 g—26 weeks50
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride
2002 · calcium-vitamin D-placebo group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D
1 g800 IU1 year49
Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents
2019 · Ca3D group · Healthy Chinese adolescents aged 11.9–15.2 years
300 mg400 IU548 days49
A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study
2006 · teriparatide group · Postmenopausal Asian women with osteoporosis
500 mg—26 weeks47
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial
2009 · control group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL
500 mg—2 years47
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial
2009 · treatment group · Kidney transplant recipients with parathyroid hormone level at least 150 pg/mL
500 mg—2 years46
Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids
2009 · Group B · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids
1 g—1 year46
Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride
2002 · calcium-vitamin D-fluoride group · Adults with inflammatory bowel disease and osteoporosis (lumbar spine T score below -2 standard deviations), median age 35 years; normal serum 25OH vitamin D
1 g800 IU1 year45
Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation
2004 · calcitriol therapy (CT) · renal transplant recipients; age and sex not specified
500 mg0.25 mcg90 days45
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study
2011 · Risedronate plus calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation
1 g800 IU1 year45
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation
2006 · ALN 70 mg weekly · Patients with orthotopic liver transplantation
1 g0.5 mcg2 years44
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study
2011 · Calcium and vitamin D3 · Patients with osteopenia or osteoporosis within the first month after liver transplantation
1 g800 IU1 year44
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
2014 · Control Group (CG) · Postmenopausal women, mean age 58.8 ± 6.4 years
500 mg1,000 IU24 weeks44
A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV
2019 · Low VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy
1 g1,000 IU1 year43
A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV
2019 · Moderate VitD group · Postmenopausal African American or Hispanic women aged 40–70 with HIV, serum 25-OHD 10–32 ng/mL, on stable antiretroviral therapy
1 g3,000 IU1 year42
The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis
2004 · Calcitriol and calcium group · Post-menopausal women with osteoporosis
1 g0.5 mcg26 weeks40
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study
2005 · Treatment group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures
1 g400 IU548 days40
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old
630 mg400 IU26 weeks40
Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
1994 · 1 alpha(OH)D3 treatment · Postmenopausal Japanese women with osteoporosis; mean age 71.9 years
300 mg—1 year40
Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis
2003 · Neridronate group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak
500 mg—3 years39
Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis
2003 · Control group · Postmenopausal women with spine bone mineral density at least 2.5 SD below peak
500 mg—3 years39
Skeletal site-dependent response of bone mineral density and quantitative ultrasound parameters following a 12-month dietary intervention using dairy products fortified with calcium and vitamin D: the Postmenopausal Health Study
2006 · dairy group (DG) · Postmenopausal women aged 55–65 years
1.2 g7.5 mcg1 year39
Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study
2007 · dairy intervention group · postmenopausal women
1.2 g7.5 mcg1 year39
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
2011 · control group · Postmenopausal Korean women over 60 years old
630 mg400 IU26 weeks38
Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women
2022 · Supplement group (S) · Overweight/obese, generally healthy postmenopausal women with dietary calcium intake of 800 mg/day or less
315 mg200 IU26 weeks37
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial
2003 · Group 2 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis
1 g800 IU1 year36
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial
2003 · Group 1 · Women aged 70 years or older with BMI ≤21 kg/m² and hip osteoporosis
1 g800 IU1 year35
The effects of a 30-month dietary intervention on bone mineral density: the Postmenopausal Health Study
2010 · dietary group (DG) · Postmenopausal women aged 55–65 years
1.2 g—913 days35
Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial
2011 · Vitamin D3 · Adults aged 18–50 with clinically definite multiple sclerosis, fully ambulatory (EDSS ≤4.5)
500 mg2,857 IU96 weeks35
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women
2002 · placebo · Postmenopausal African-American women aged 45–88 with osteoporosis
500 mg500 IU2 years33
Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake
2005 · WL Hi-Ca · Overweight postmenopausal women aged 50–75 undergoing weight loss
1.2 g400 IU180 days33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · raloxifene group · Postmenopausal women with diagnosed osteoporosis
500 mg800 IU2 years33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · placebo group · Postmenopausal women with diagnosed osteoporosis
500 mg800 IU2 years33
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis
2006 · continuation of open-label alendronate group · Postmenopausal women with diagnosed osteoporosis
500 mg800 IU2 years33
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women
2002 · alendronate group · Postmenopausal African-American women aged 45–88 with osteoporosis
500 mg500 IU2 years32
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D
2011 · group A · Patients with Crohn's disease and reduced BMD (T-score < -1)
800 mg1,000 IU1278 days32
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study
2005 · Control group · Men with idiopathic osteoporosis, mean age 59 ± 6 years, without vertebral fractures
1 g400 IU548 days31
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH250 · Adults aged 52–84 years with osteoporosis
300 mg200 IU90 days31
Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial
2004 · treatment group · Healthy adults; age and sex not specified
500 mg500 IU213 days30
[Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis]
2005 · Group A · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment
2.25 g1 mcg1 year30
[Prevention of glucocorticoid-induced osteoporosis in patients with primary glomerulonephritis]
2005 · Group B · Adults aged 18–50 with primary glomerulonephritis receiving glucocorticoid treatment
2.25 g0.5 mcg1 year30
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH500 · Adults aged 52–84 years with osteoporosis
300 mg200 IU90 days30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group A · Adults with established postmenopausal or male osteoporosis
500 mg1 mcg2 years30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group B · Adults with established postmenopausal or male osteoporosis
1 g1,000 IU2 years30
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
2007 · group C · Adults with established postmenopausal or male osteoporosis
500 mg1 mcg2 years30
Clodronic acid in the treatment of postmenopausal osteoporosis
2007 · clodronic acid group · Postmenopausal women aged 48–73 years with osteoporosis
500 mg400 IU3 years30
Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial
2013 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low-calcium diets
600 mg200 IU—30
Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial
2016 · calcium plus cholecalciferol · Pregnant adolescents aged 14–19 years
600 mg200 IU—30
Reduction in Bone Loss from 5 to 20 Weeks Postpartum in Adolescents Supplemented with Calcium Plus Vitamin D during Pregnancy Is Not Sustained at 1 Year Postpartum: Follow-up Study of a Randomized Controlled Trial
2021 · supplemented group · Pregnant adolescents aged 14–19 years with habitually low calcium intake
600 mg200 IU—30
Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation
1997 · treatment group · Patients with hemiplegia after stroke; mean duration of illness 4.8 years; age and sex not reported
300 mg1 mcg26 weeks30
Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study
2006 · PTH1000 · Adults aged 52–84 years with osteoporosis
300 mg200 IU90 days29
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)
2008 · Control group · Adults aged 18 years or older with cystic fibrosis and low bone mass
500 mg800 IU1 year29
Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial
2015 · Resistance training (RT) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active
1 g10 mcg1 year29
Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: A 12-month randomized, clinical trial
2015 · Jump training (JUMP) · Men aged 25–60 years with low lumbar-spine or hip bone mass; apparently healthy and physically active
1 g10 mcg1 year29
[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]
2002 · alendronate group · Postmenopausal women with osteopenia or osteoporosis
600 mg—26 weeks28
[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]
2002 · placebo group · Postmenopausal women with osteopenia or osteoporosis
600 mg—26 weeks28
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · B · Adults aged 61–96 years with a recent hip fracture
1 g800 IU1 year28
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)
2008 · Alendronate group · Adults aged 18 years or older with cystic fibrosis and low bone mass
500 mg800 IU1 year27
Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss?
2009 · Group A · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion
100 mg200 IU1 year26
Bone mass decreases in morbidly obese women after long limb-biliopancreatic diversion and marked weight loss without secondary hyperparathyroidism. A physiological adaptation to weight loss?
2009 · Group B · Healthy, morbidly obese, premenopausal women undergoing long limb-biliopancreatic diversion
2.1 g200 IU1 year26
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaD group · Postmenopausal women
800 mg10 mcg1 year26
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK1 group · Postmenopausal women
800 mg10 mcg1 year26
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · BN · Adults aged 61–96 years with a recent hip fracture
1 g800 IU26 weeks26
Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
2014 · C · Adults aged 61–96 years with a recent hip fracture
1 g800 IU1 year25
Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial
2017 · multispecies probiotic supplement (GeriLact) · Postmenopausal women aged 50–72 years with osteopenia
500 mg200 IU26 weeks25
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK2 group · Postmenopausal women
800 mg10 mcg1 year24
Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)
2012 · placebo group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated
500 mg—96 weeks24
Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women
1998 · E + C group · Postmenopausal women with at least one non-traumatic vertebral fracture or z score < -1.5
500 mg0.5 mcg1 year24
Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids
2009 · Group A · Patients with rheumatic diseases, osteopenia or osteoporosis, and gastric or esophageal conditions contraindicating oral bisphosphonates; receiving chronic low-dose glucocorticoids
1 g—1 year23
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome
2009 · group 1 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia
500 mg800 mg1 year23
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome
2009 · group 2 · Premenopausal women aged 43.1 ± 7.7 years with subclinical Cushing's syndrome due to adrenal incidentaloma and osteoporosis or osteopenia
500 mg800 mg1 year23
Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography
2004 · RLX 120 mg/day · Postmenopausal women with osteoporosis
500 mg—2 years20
Effects of neridronate treatment in elderly women with osteoporosis
2005 · Neridronate plus calcium and vitamin D · Postmenopausal women aged 65–80 with osteoporosis
500 mg—1 year20
Effects of neridronate treatment in elderly women with osteoporosis
2005 · Calcium plus vitamin D supplements alone · Postmenopausal women aged 65–80 with osteoporosis
500 mg—1 year20
Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study
2011 · dietary group (DG) · Postmenopausal women aged 55–65 with osteopenia
1.2 g—913 days20
Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT
2012 · Algal oil containing DHA · Individuals with osteopenia
1.2 g1,000 IU1 year20
Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT
2012 · Placebo group · Individuals with osteopenia
1.2 g1,000 IU1 year20
Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)
2012 · alendronate group · HIV-1-infected adults with low bone mineral density and no other known risk factors for low BMD; antiretroviral-treated
500 mg—96 weeks20
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
1998 · Combined therapy group · Postmenopausal women with established osteoporosis; mean age 64.9 years
1 g—4 years19
Increase of bone mineral density with sodium fluoride in patients with Crohn's disease
2000 · calcium/vitamin D/fluoride group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year
1 g1,000 IU1 year18
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation
2000 · Control subjects · Patients with cystic fibrosis after lung transplantation
1 g800 IU2 years18
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
1998 · Control group · Postmenopausal women with established osteoporosis; mean age 64.9 years
1 g—4 years18
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
1998 · HRT group · Postmenopausal women with established osteoporosis; mean age 64.9 years
1 g—4 years18
Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography
2004 · RLX 60 mg/day · Postmenopausal women with osteoporosis
500 mg—2 years17
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
1998 · Etidronate group · Postmenopausal women with established osteoporosis; mean age 64.9 years
1 g—4 years17
Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation
2000 · treatment group · Long-term renal transplant recipients with serum creatinine levels less than 2.0 mg/dL
500 mg0.25 mcg1 year16
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation
2000 · Pamidronate treatment group · Patients with cystic fibrosis after lung transplantation
1 g800 IU2 years16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · SrRan monotherapy · Postmenopausal women aged 54–73 with osteoporosis
1 g800 IU26 weeks16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · SrRan + AD3 · Postmenopausal women aged 54–73 with osteoporosis
1 g800 IU26 weeks16
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis
2014 · Control · Postmenopausal women aged 54–73 with osteoporosis
1 g800 IU26 weeks16
Increase of bone mineral density with sodium fluoride in patients with Crohn's disease
2000 · calcium/vitamin D only group · Patients with chronic active Crohn's disease and osteoporosis; all had received systemic high-dose steroid therapy during the previous year
1 g1,000 IU1 year15
Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis
2004 · calcium and vitamin D treatment group · Adults with cystic fibrosis and a BMD Z score of -1 or less in the lumbar spine, proximal femur or distal forearm
1 g1,700 IU1 year15
Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study
2013 · Group B (drug arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density
1 g—1 year15
Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate
1994 · treated group · Adults with asthma undergoing long-term systemic corticosteroid treatment
1 g1,000 IU26 weeks14
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers
2000 · Vehicle group · Men aged 30–68 with idiopathic osteoporosis
1.5 g400 IU548 days13
Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study
2013 · Group A (control arm) · Adults aged 18 years or older with newly diagnosed celiac disease and low bone mineral density
1 g—1 year13
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers
2000 · PTH-(1-34) group · Men aged 30–68 with idiopathic osteoporosis
1.5 g400 IU548 days10
Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial
2020 · study group · Adults aged 18–50 with HIV infection, ART-naïve at enrollment and starting TDF/FTC/EFV; mostly men
1.25 g2,857 IU24 weeks9
Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study
1996 · Group 1 · Adults with renal grafts or skin, bronchopulmonary, or Crohn's disease, chronically treated with glucocorticosteroids
1 g—1 year8
Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients
1997 · diet plus calcium and vitamin D · Adults with newly diagnosed, untreated celiac disease; 11 of the 14 patients had osteopenia at diagnosis
1 g4,571 IU1 year7
Prevention of bone loss after withdrawal of tamoxifen
2008 · alendronate group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years
1.2 g—1 year6
Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women
1990 · Ergocalciferol-treated group · Women over 60 years of age with osteopenia
1 g—1 year6
Prevention of bone loss after withdrawal of tamoxifen
2008 · placebo group · Postmenopausal women with a history of breast cancer who had stopped tamoxifen; mean age 58 years
1.2 g—1 year5
Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women
1990 · Calcitriol-treated group · Women over 60 years of age with osteopenia
1 g0.5 mcg1 year4
Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol
1999 · calcitriol group · Adults after cardiac transplantation; mean age 51 years, 111 male and 21 female across the study; sex-specific arm ages not reported
1 g—3 years—
Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
2000 · calcium and calcitriol at 0.25 microg daily · Thai postmenopausal women no more than 6 years postmenopausal
750 mg0.25 mcg2 years—
Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
2000 · calcium and calcitriol at 0.5 microg daily · Thai postmenopausal women no more than 6 years postmenopausal
750 mg0.5 mcg2 years—
Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study
2000 · Group 1 · Premenopausal women aged 31.1 ± 6 years with systemic lupus erythematosus taking chronic steroid therapy
1.2 g0.5 mcg2 years—
Effect of calcitriol on bone loss after cardiac or lung transplantation
2000 · Calcitriol for 12 months followed by calcium for 12 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified
600 mg—2 years—
Effect of calcitriol on bone loss after cardiac or lung transplantation
2000 · Calcitriol for 24 months · Patients undergoing cardiac or single lung transplantation; age and sex not specified
600 mg—2 years—
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis
2001 · HEBP group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain
2 g0.5 mcg2 years—
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis
2001 · Ca. D group · Women over 50 years old with postmenopausal osteoporosis, low BMD and lumbo-dorsal pain
2 g0.5 mcg2 years—
Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study
2002 · CaD group · Adult renal transplant recipients; 65 men and 46 women, mean age 47 years
1 g0.25 mcg26 weeks—
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate
2003 · group A · Patients with Crohn's disease and pathological bone mineral density findings
800 mg1,000 IU821 days—
Vitamin D supplementation and bone mineral density in early postmenopausal women
2003 · 1000 mg Ca/d plus 10 000 U vitamin D(2)/wk · Postmenopausal women at least 1 year after menopause; mean age 56 years
1 g—2 years—
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density
2003 · HRT/D group · Postmenopausal women aged 53–79 years with osteoporosis, at least one minimal-trauma vertebral fracture, and low lumbar bone mineral density
600 mg0.5 mcg2 years—
Preventing bone loss in renal transplant recipients with vitamin D
2003 · group 1 · adult men who were recent renal transplant recipients
500 mg0.5 mcg——
A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease
2003 · calcium and vitamin D alone · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip
500 mg400 IU1 year—
A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease
2003 · calcium and vitamin D with intravenous pamidronate · Patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip
500 mg400 IU1 year—
An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis
2004 · Transdermal HRT group · Postmenopausal women with primary biliary cirrhosis
1 g0.25 mcg2 years—
An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis
2004 · Control group · Postmenopausal women with primary biliary cirrhosis
1 g0.25 mcg2 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · alendronate 10 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT
500 mg250 IU3 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · alendronate 5 mg/day group · Women aged 60–86 years with low BMD who had received alendronate in FIT
500 mg250 IU3 years—
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension
2004 · placebo group · Women aged 60–86 years with low BMD who had received alendronate in FIT
500 mg250 IU3 years—
The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study
2004 · vitamin D3 plus calcium · Women aged 58–88 with a proximal humerus fracture and osteoporosis or osteopenia
1 g800 IU12 weeks—
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease
2005 · Etidronate group · Patients with Crohn's disease and decreased bone mineral density
500 mg400 IU2 years—
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease
2005 · Non-etidronate group · Patients with Crohn's disease and decreased bone mineral density
500 mg400 IU2 years—
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate
2005 · Calcium, vitamin D, and sex hormone replacement group · Adults who received an allogeneic stem cell transplant
1 g800 IU1 year—
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate
2005 · Calcium, vitamin D, sex hormone replacement, and pamidronate group · Adults who received an allogeneic stem cell transplant
1 g800 IU1 year—
A prospective randomized study for prevention of postrenal transplantation bone loss
2005 · group I · adult male recent renal transplant recipients
500 mg0.5 mcg1 year—
Effects of calcium, dairy product, and vitamin D supplementation on bone mass accrual and body composition in 10-12-y-old girls: a 2-y randomized trial
2005 · calcium (1000 mg) + vitamin D3 (200 IU) · Healthy girls aged 10–12 years at Tanner stage I–II with dietary calcium intake below 900 mg/day
1 g200 IU2 years—
Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome
2006 · treatment group · Children with nephrotic syndrome receiving prednisolone; mean age 4.6 years, 27 boys and 13 girls across the study
1 g400 IU60 days—
Calcium plus vitamin D supplementation and the risk of fractures
2006 · calcium plus vitamin D group · Healthy postmenopausal women aged 50 to 79 years
1 g400 IU7 years—
Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial
2006 · calcium- and vitamin D3-fortified milk group · Men older than 50 years living in the community; mean age 61.9 years
1 g800 IU2 years—
Long-term effects of calcium-vitamin-D3-fortified milk on bone geometry and strength in older men
2006 · milk supplementation group · men aged over 50 years; older subgroup analyses included men over 62 years
1 g800 IU2 years—
Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations
2007 · calcium + vitamin D supplement group · Healthy overweight or obese women with daily calcium intake below 800 mg
1.2 g400 IU15 weeks—
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · vitamin D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older
1 g10 mcg2 years—
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older
1 g10 mcg2 years—
Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D
2007 · calcium and vitamin D intervention group · Patients with a recent low-energy fracture of the hip, forearm, shoulder, or spine; mean age 70 ± 11 years, 84% women
3 g1,400 IU1 year—
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis
2007 · Raloxifene group · Postmenopausal women with osteoporosis
600 mg400 IU1 year—
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis
2007 · Low-dose HRT group · Postmenopausal women with osteoporosis
600 mg400 IU1 year—
Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial
2008 · CaD group · Community-dwelling women aged 70–80 years
1.2 g1,000 IU5 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 2 mg IV ibandronate every 2 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
500 mg400 IU2 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 3 mg IV ibandronate every 3 months · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
500 mg400 IU2 years—
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
2008 · 2.5 mg daily oral ibandronate · Women aged 55–80 years, at least 5 years postmenopause, with osteoporosis
500 mg400 IU2 years—
Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency
2008 · Calcium plus vitamin D · Elderly women, mean age 77.2 years, with vitamin D insufficiency (serum 25(OH)D <60 nM)
1 g1,000 IU1 year—
Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women
1991 · Vitamin D group · Healthy, ambulatory postmenopausal women with usual vitamin D intakes of 100 IU/day
377 mg400 IU1 year—
Effect of alendronate in elderly patients after low trauma hip fracture repair
2009 · Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women
500 mg400 IU1 year—
Effect of alendronate in elderly patients after low trauma hip fracture repair
2009 · ALN + Ca-Vit D group · Elderly patients after low-trauma hip fracture repair; mean age 81 ± 7 years; 79.8% women
500 mg400 IU1 year—
Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial
2009 · exercise + fortified milk · Men aged 50–79 years; older, well-nourished men
1 g800 IU1 year—
Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial
2009 · fortified milk · Men aged 50–79 years; older, well-nourished men
1 g800 IU1 year—
Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial
2008 · calcium supplementation group · Children aged 6–18 years with juvenile rheumatoid arthritis, without systemic corticosteroid therapy in the 3 months before enrollment
1 g400 IU2 years—
Vitamin D insufficiency does not affect response of bone mineral density to alendronate
2009 · Calcium and cholecalciferol recipients · Postmenopausal women with low bone mineral density
500 mg250 IU——
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
2009 · upfront zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole
1 g—5 years—
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
2009 · delayed zoledronic acid arm · Postmenopausal women with stage I–IIIa hormone receptor-positive breast cancer who had completed up to 6 years of tamoxifen and were starting letrozole
1 g—5 years—
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
2009 · DHEA group · Men and women aged 65–75 years
700 mg16 mcg2 years—
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
2009 · Placebo group, then open-label DHEA in year 2 · Men and women aged 65–75 years
700 mg16 mcg1 year—
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis
2010 · Tricalcium phosphate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day
1.8 g1,000 IU1 year—
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis
2010 · Calcium carbonate group · Patients with osteoporosis treated with teriparatide and consuming less than 1000 mg phosphorus per day
1.8 g1,000 IU1 year—
Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass
2011 · Alfa/ALN group · Postmenopausal women aged 73.6 ± 4.7 years with osteoporosis or osteopenia
500 mg—3 years—
The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial
2012 · high-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip)
1 g—1 year—
The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial
2012 · standard-dose vitamin D group · Postmenopausal women aged 50–80 years with reduced bone mass (BMD T-score ≤ −2.0 in the lumbar spine or total hip)
1 g800 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Placebo group · Japanese postmenopausal women with osteoporosis
600 mg400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 14 mg group · Japanese postmenopausal women with osteoporosis
600 mg400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 60 mg group · Japanese postmenopausal women with osteoporosis
600 mg400 IU1 year—
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
2012 · Denosumab 100 mg group · Japanese postmenopausal women with osteoporosis
600 mg400 IU1 year—
Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study
1990 · calcitriol · Postmenopausal women with vertebral fractures; age range not reported
600 mg0.62 mcg2 years—
Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
2012 · denosumab group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy
1 g—3 years—
Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
2012 · placebo group · Men aged 70 years or older, or younger men with osteoporotic fracture history or low BMD, with nonmetastatic prostate cancer receiving androgen-deprivation therapy
1 g—3 years—
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
2012 · Ibandronate group · Renal transplant recipients with early stable renal function
1 g0.25 mcg1 year—
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
2012 · Placebo group · Renal transplant recipients with early stable renal function
1 g0.25 mcg1 year—
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis
2013 · low-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis
600 mg125 IU1 year—
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis
2013 · standard-dose ALN group · Chinese postmenopausal women aged 62.2 ± 7.0 years with osteopenia or osteoporosis
600 mg125 IU1 year—
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial
2013 · Control group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy
1.2 g—1 year—
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial
2013 · Zoledronic acid group · Adults aged 18 years or older with newly diagnosed lymphoma, without osteoporosis; vitamin D- or testosterone-deficient patients were eligible if receiving appropriate therapy
1.2 g—1 year—
Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study
2014 · D+ · Adults with primary hyperparathyroidism after successful parathyroidectomy; median age 60 years, range 30–80; 79% women
1 g1,600 IU1 year—
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
2014 · Exemestane group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0
1 g800 IU2 years—
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
2014 · Anastrozole group · Postmenopausal women with early hormone-receptor-positive breast cancer, with baseline bone mineral density T-scores of either −2.0 or greater or less than −2.0
1 g800 IU2 years—
The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial
2014 · 100 g dried plum/d group · Osteopenic postmenopausal women
500 mg400 IU1 year—
The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial
2014 · 75 g dried apple/d comparative control group · Osteopenic postmenopausal women
500 mg400 IU1 year—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · Low-Ca group · Girls and boys aged 12–14 years
300 mg200 IU2 years—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · Mid-Ca group · Girls and boys aged 12–14 years
600 mg200 IU2 years—
Effects of milk salt supplementation on bone mineral gain in pubertal Chinese adolescents: a 2-year randomized, double-blind, controlled, dose-response trial
2014 · High-Ca group · Girls and boys aged 12–14 years
600 mg200 IU2 years—
A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial
2015 · CC group · Postmenopausal women with osteopenia
500 mg200 IU1 year—
A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial
2015 · Control group · Postmenopausal women with osteopenia
500 mg200 IU1 year—
Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis
2016 · SrR group · Women with thalassemia major-related osteoporosis
1 g800 IU2 years—
Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study
2015 · GH 1.0 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement
750 mg—3 years—
Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study
2015 · GH 2.5 U group · Women aged 50–70 with postmenopausal osteoporosis receiving estrogen hormone replacement
750 mg—3 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group A · Postmenopausal women aged 50–65 years
300 mg800 IU2 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group B · Postmenopausal women aged 50–65 years
600 mg800 IU2 years—
Effect of Milk Powder Supplementation with Different Calcium Contents on Bone Mineral Density of Postmenopausal Women in Northern China: A Randomized Controlled Double-Blind Trial
2016 · Group C · Postmenopausal women aged 50–65 years
900 mg800 IU2 years—
Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy
2017 · Cholecalciferol and calcium carbonate · Adults with primary hyperparathyroidism undergoing parathyroidectomy; median age 60 years, 119 women
1 g1,600 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · PATCH · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside hormone treatment
1.2 g800 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · PILL · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation alongside combined oral contraceptive treatment
1.2 g800 IU1 year—
Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial
2019 · NONE · Females aged 14–25 years with oligo-amenorrhoea who were endurance athletes; received the shared calcium and vitamin D supplementation and no oestrogen or progesterone
1.2 g800 IU1 year—
Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women
2019 · Supplement group (S) · Overweight or obese Caucasian women 2–10 years postmenopausal, generally healthy, with dietary calcium intake of 800 mg/day or less
630 mg400 IU26 weeks—
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
2020 · Co-supplementation group · Community-dwelling men and postmenopausal women aged 50–75 years
500 mg10 mcg1 year—
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia
800 mg38 mcg1096 days—
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
2021 · Placebo group · Postmenopausal women with osteopenia
800 mg38 mcg1096 days—
Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial
2021 · standard-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART
1.2 g400 IU48 weeks—
Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial
2021 · high-dose VitD/Ca supplementation · Adolescents aged 10–20 years with perinatally acquired HIV who were on stable cART
1.2 g3,257 IU48 weeks—
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia
2022 · Group A · Postmenopausal women with osteopenia
500 mg400 IU1 year—
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
2024 · Arm 2 (placebo arm; daily supplements) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL
1.01 g800 IU24 weeks—
Impact of high-dose vitamin D and calcium carbonate supplementation on bone density in adolescents living with HIV: a randomised, placebo-controlled trial
2026 · intervention · Adolescents aged 11–19 years with perinatally acquired HIV, taking antiretroviral therapy
500 mg2,857 IU48 weeks—
Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin
1993 · Calcitriol plus salmon calcitonin · Patients starting long-term corticosteroid therapy
1 g—1 year—
Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin
1993 · Calcitriol plus placebo nasal spray · Patients starting long-term corticosteroid therapy
1 g—1 year—
Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D
1995 · 2.5 micrograms (100 IU) vitamin D/d group · Healthy ambulatory postmenopausal women
500 mg100 IU2 years—
Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D
1995 · 17.5 micrograms (700 IU) vitamin D/d group · Healthy ambulatory postmenopausal women
500 mg700 IU2 years—
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss
1994 · calcium augmentation · Healthy white women 3 to 6 years after spontaneous menopause
1.7 g400 IU1059 days—
Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss
1994 · estrogen-progesterone-calcium · Healthy white women 3 to 6 years after spontaneous menopause
1.7 g400 IU1059 days—
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial
1996 · Calcium carbonate and vitamin D3 · Patients with rheumatoid arthritis; some were receiving corticosteroids and some were not
1 g500 IU2 years—
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
1997 · calcium and vitamin D group · Men and women 65 years of age or older living at home
500 mg700 IU3 years—
Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women
1998 · Calcium and vitamin D supplement group · Healthy postmenopausal women aged 58–67
1 g—2 years—
[Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial]
2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported
1.2 g400 IU1 year125
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
2018 · VITD3 group · Youth aged 16–24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy for at least 180 days
162 mg—48 weeks109
Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year
2018 · intervention · Chinese postmenopausal women in Malaysia; mean age 59 years
1.2 g15 mcg1 year61
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study
2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding
500 mg800 IU26 weeks31
The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study
2016 · intervention group · Women and similarly aged men with BMI >38 kg/m² after Roux-en-Y gastric bypass or sleeve gastrectomy; median age 40.7 years
1 g6,286 IU2 years—
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
2024 · Arm 1 (high-dose vitamin D) · Men aged 60 years or older with stage I–IV prostate cancer, no bone metastases, receiving androgen deprivation therapy, and serum 25(OH)D below 32 ng/mL
1.01 g7,943 IU24 weeks—
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Randomized trial, denosumab group · Infertile men; mean age approximately 34 years
400 mg25 mcg160 days49
Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving
2009 · Vitamin D- and calcium-fortified bun · Older nursing home residents; sex and age range not reported; vitamin D-deficient
320 mg125 mcg1 year45
Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass
2009 · calcium citrate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man
500 mg62.5 IU1 day18
Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass
2009 · calcium carbonate phase · Adults aged 30–61 years who had undergone Roux-en-Y gastric bypass approximately 1 year earlier; 17 women and 1 man
500 mg125 IU1 day18
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
2006 · 125 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years
500 mg125 mcg90 days13
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
2006 · 250 microg/day vitamin D(2) group · Postmenopausal women with osteopenia or osteoporosis; median age 61.5 years
500 mg250 mcg90 days12
Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report
2010 · GTP group · Postmenopausal women with osteopenia; at least 2 years after menopause
500 mg200 IU24 weeks47
Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report
2010 · Placebo + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause
500 mg200 IU24 weeks42
Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report
2010 · GTP + TC group · Postmenopausal women with osteopenia; at least 2 years after menopause
500 mg200 IU24 weeks38
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Pilot cohort · Infertile men; mean age 33.4 years
400 mg25 mcg270 days12
Calcium absorption in postmenopausal osteoporosis: benefit of HRT plus calcitriol, but not HRT alone, in both malabsorbers and normal absorbers
2000 · HRT plus calcitriol · Postmenopausal women with osteoporosis and vertebral compression fractures; age not reported
600 mg—243 days—
Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure
2008 · CaD group · Ambulatory men with congestive heart failure, low vitamin D status, and insufficient dietary calcium intake
500 mg50 mcg270 days—
[Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes]
2011 · group I · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis
440 mg100 IU1 year—
Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial
2012 · Placebo · Postmenopausal women with osteopenia
500 mg200 IU26 weeks—
Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial
2012 · GTP · Postmenopausal women with osteopenia
500 mg200 IU26 weeks—
Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial
2012 · Placebo + TC · Postmenopausal women with osteopenia
500 mg200 IU26 weeks—
Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial
2012 · GTP + TC · Postmenopausal women with osteopenia
500 mg200 IU26 weeks—
Calcium plus vitamin D supplementation during pregnancy has no impact on postpartum transient longitudinal changes in hip geometry in adolescent mothers: a secondary analysis of a randomised controlled trial
2024 · calcium plus vitamin D · Pregnant adolescents aged 14–19 years with low daily calcium intake (approximately 600 mg/day); lactating postpartum adolescents were assessed
600 mg200 mcg——
SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial
2017 · D&Cancer Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health
1.5 g2,000 IU1 year915
Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients
2014 · strontium ranelate 2 g/vitamin D₃ 1000 IU daily · Men and postmenopausal women aged 50 years or older with primary osteoporosis and serum 25(OH)D >22.5 nmol/l
1 g1,000 IU26 weeks413
Does Vitamin D3 Supplementation Improve Depression Scores among Rural Adolescents? A Randomized Controlled Trial
2024 · calcium intervention arm · Rural adolescent boys and girls aged 14–19 years with any form of depression
500 mg250 IU9 weeks216
SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial
2017 · CaMEWS Ca + D group · Postmenopausal non-Hispanic white women aged 55 years or older, in good general health
1.5 g1,100 IU1 year203
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study
2002 · calcium-vitamin D3 fixed combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population
1.2 g800 IU2 years199
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study
2002 · calcium plus vitamin D3 separate combination group · Ambulatory institutionalized women; mean age 85.2 years; vitamin D insufficiency and low calcium intake described in the study population
1.2 g800 IU2 years190
Type of dietary fat is associated with the 25-hydroxyvitamin D3 increment in response to vitamin D supplementation
2011 · active treatment arm · Healthy men and women aged 65 and older
500 mg700 IU2 years152
Body size and serum 25 hydroxy vitamin D response to oral supplements in healthy older adults
2008 · calcium-vitamin D supplementation treatment group · Men and women aged 65 years or older; healthy and ambulatory
500 mg700 IU3 years132
Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study
2021 · Group A (2000 IU) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 50 years; treated in orthopaedic, obstetrics and gynaecology clinics
600 mg2,000 IU90 days121
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
2018 · ALN/D5600 · Postmenopausal women in China aged over 55 with postmenopausal osteoporosis
500 mg800 IU1 year111
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
2021 · Low dose (600 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL
1 g600 IU1 year111
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
2021 · High dose (3750 IU/day) · Lebanese women and men aged 65 years or older who were overweight or obese and had baseline serum 25(OH)D of 10–30 ng/mL
1 g3,750 IU1 year110
Time out: should vitamin D dosing be based on patient's body mass index (BMI): a prospective controlled study
2021 · Group B (125 IU/kg/m²) · Women with vitamin D deficiency and BMI ≥30 kg/m²; mean age 52 years; treated in orthopaedic, obstetrics and gynaecology clinics
600 mg—90 days109
Response of serum 25(OH)D to Vitamin D and calcium supplementation in school-children from a semi-rural setting in India
2018 · Daily vitamin D and calcium supplementation · Schoolchildren aged 6–12 years, boys and girls, from a semi-rural setting in India; baseline vitamin D status varied
500 mg1,000 IU26 weeks106
Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks
2018 · depot therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L
200 mg—40 weeks84
Randomised Controlled Trial Comparing Daily Versus Depot Vitamin D3 Therapy in 0-16-Year-Old Newly Settled Refugees in Western Australia Over a Period of 40 Weeks
2018 · daily therapy · Refugee children aged 5.5 months to 16 years with serum 25(OH)D below 78 nmol/L
200 mg—40 weeks73
A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects
2022 · Vitamin D3 + Calcium · Adults aged 18 years and over, men and women, with vitamin D deficiency; apparently healthy community-dwelling UAE residents and expatriates
600 mg2,000 IU26 weeks68
Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial
2014 · 400 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months
200 mg400 IU26 weeks67
Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial
2011 · vitamin D3-fortified doogh (FYD) · Adults aged 29–67 years with type 2 diabetes; 57 women and 43 men overall
340 mg1,000 IU12 weeks50
Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes
2012 · vitamin D3-fortified doogh (FD) · People with type 2 diabetes
340 mg1,000 IU12 weeks50
Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial
2023 · Daily (D) group · Infants with symptomatic vitamin D deficiency
50 mg/kg2,000 IU90 days46
Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents
1995 · G1 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure
1 g800 IU26 weeks46
Evaluation of a new solid formulation of calcium and vitamin D in institutionalized elderly subjects. A randomized comparative trial versus separate administration of both constituents
1995 · G2 · Institutionalized elderly subjects, mean age 83.1 years, with vitamin D deficiency and without severe renal failure
1 g800 IU26 weeks45
Daily vs. monthly oral vitamin D(3) for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial
2023 · Bolus (B) group · Infants with symptomatic vitamin D deficiency
50 mg/kg—90 days44
Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial
2024 · group daily (D) · Children aged 1–10 years with symptomatic vitamin D deficiency
500 mg4,000 IU12 weeks40
Daily versus fortnightly oral vitamin D(3) in treatment of symptomatic vitamin D deficiency in children aged 1-10 years: An open labelled randomized controlled trial
2024 · group bolus (B) · Children aged 1–10 years with symptomatic vitamin D deficiency
500 mg—12 weeks40
Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial
2021 · vitamin D3 monthly group (VDM) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle
400 mg—14 weeks37
Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial
2009 · group 1 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass
1.5 g7,943 IU1 year30
Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial
2009 · group 2 · Morbidly obese women with vitamin D depletion after Roux-en-Y gastric bypass
1.5 g800 IU1 year30
Effects of Vitamin D3 Supplementation and Resistance Training on 25-Hydroxyvitamin D Status and Functional Performance of Older Adults: A Randomized Placebo-Controlled Trial
2021 · vitamin D3 daily group (VDD) · Adults aged 65–85 years, community-dwelling, with low-to-moderate baseline vitamin D levels; independent lifestyle
400 mg800 IU14 weeks30
Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents
2009 · VD+ · HIV-infected children and adolescents aged 6–16 years
1 g—1 year29
Fortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling Home
2015 · Fortified Yogurt (FY) · Women aged 61–90 with serum 25OHD ≤20 ng/mL, living in community sheltered accommodation
520 mg10 mcg12 weeks28
Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome
2015 · 1000 mg calcium/d + 50,000 IU/wk vitamin D · Overweight and obese vitamin D deficient women diagnosed with PCOS
1 g7,143 IU8 weeks26
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight loss and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss
1.2 g10 mcg6 weeks22
Effects of vitamin D3 and calcium supplementation on serum levels of tocopherols, retinol, and specific vitamin D metabolites
2012 · calcium plus vitamin D3 · Adults aged 30–75 in general health with a history of at least one pathology-confirmed adenomatous colorectal polyp within the previous 36 months
2 g800 IU26 weeks21
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight maintenance and placebo · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance
1.2 g10 mcg6 weeks21
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight maintenance and vitamin D3-supplementation (WM-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight maintenance
1.2 g63.6 mcg6 weeks20
Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation
2013 · Vitamin D3 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency
675 mg400 IU90 days20
Vitamin D supplementation and calcium absorption during caloric restriction: a randomized double-blind trial
2013 · weight loss and vitamin D3-supplementation (WL-D) · Postmenopausal women with 25(OH)D concentrations <70 nmol/L assigned to weight loss
1.2 g63.6 mcg6 weeks19
Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D₃ or D₂supplementation
2013 · Vitamin D2 group · Healthy adults aged 15–70 years, both sexes; some had vitamin D deficiency
500 mg400 IU90 days19
Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation
2025 · VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase
1 g4,000 IU6 weeks17
Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D₃ per day: a randomized clinical trial
2012 · oral vitamin D(3) and calcium group · Participants with vitamin D deficiency (25(OH)D(3) ≤ 25 nmol L(-1)); age and sex not reported
1 g1,600 IU6 weeks16
Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study
2010 · Silicon-rich Water (SW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA
1.2 g800 IU14 weeks10
Calcium and vitamin D intakes in children: a randomized controlled trial
2013 · Group 1 (dietary counseling plus Ca and Vitamin D supplementation) · Children aged 9.7–11.4 years with dietary calcium and vitamin D intake below 70% of the recommended intake
400 mg400 IU120 days10
Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study
2010 · Purified Water (PW) · Postmenopausal women within 5 years of menopause with reduced bone density but no osteopenia or osteoporosis by DEXA
1.2 g800 IU14 weeks9
A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study
2004 · injected vitamin D(2) plus oral calcium · elderly women recruited after surgery for hip fracture
1 g—1 year—
A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study
2004 · oral vitamin D(3) plus calcium · elderly women recruited after surgery for hip fracture
1 g—1 year—
Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3
2005 · Calcium group · Healthy older men and women
1 g800 IU90 days—
Which therapy to prevent post-thyroidectomy hypocalcemia?
2005 · group B · Patients undergoing total thyroidectomy for benign thyroid disease or malignancy; age and sex not specified
1.5 g———
Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults
2006 · vitamin D group · Healthy university students aged 18–27 years, male and female
1.5 g15 mcg8 weeks—
Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients
2008 · Group II (400 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent
500 mg400 IU26 weeks—
Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients
2008 · Group III (1200 IU cholecalciferol per day) · Long-term inpatients aged over 65 years who were chronically bedridden; vitamin D deficiency was prevalent
500 mg1,200 IU26 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D2 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
50 mg/kg2,000 IU6 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D2 weekly · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
50 mg/kg7,143 IU6 weeks—
Treatment of hypovitaminosis D in infants and toddlers
2008 · Vitamin D3 daily · Infants and toddlers with hypovitaminosis D; exact age range and sex not reported
50 mg/kg2,000 IU6 weeks—
The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit
2008 · group 1 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit
1.25 g300,000 IU39 weeks—
The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit
2008 · group 2 · Adults aged 65–102 years with secondary hyperparathyroidism and normal or reduced serum calcium, living in a low-income housing unit
1.25 g800 IU39 weeks—
Effect of vitamin D supplementation in the institutionalized elderly
2009 · group (B) · Institutionalized elderly with low baseline vitamin D status
200 mg5 mcg30 days—
The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function
2010 · D group · Women aged 69.3–78.8 years
1 g800 IU1 year—
The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function
2010 · 4 M group · Women aged 69.3–78.8 years
1 g—1 year—
Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country?
2010 · supplement group · Postmenopausal women with osteoporosis, mean age 62 ± 8 years
1.2 g400 IU90 days—
Improvement of vitamin D status in Japanese institutionalized elderly by supplementation with 800 IU of vitamin D(3)
2009 · Ca+VD group · Institutionalized elderly; age and sex not specified; baseline serum 25-hydroxyvitamin D was in the hypovitaminosis D range
200 mg800 IU30 days—
Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention
2010 · VD and Ca (VD-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D
600 mg10 mcg1 year—
Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention
2010 · Multiple micronutrient and Ca (MMN-Ca) group · Females aged 16–36 years working in garment factories in Bangladesh with hypovitaminosis D
600 mg10 mcg1 year—
Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States
2009 · 2,000 mg calcium plus 800 IU vitamin D daily · Adults aged 30–74 with a history of at least one pathologically confirmed adenomatous colonic polyp within the previous 36 months
2 g800 IU26 weeks—
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting
2010 · high-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L
500 mg50,000 IU10 days—
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting
2010 · continuous low-dose regimen · Vitamin D-deficient inpatients with serum 25(OH)D ≤ 50 nmol/L
500 mg4,000 IU90 days—
Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomised controlled trial
2012 · vitamin D(3) plus calcium group · Community-dwelling adults aged 55–84 years
1 g40 mcg1 year—
Changes in vitamin D metabolites during teriparatide treatment
2012 · teriparatide group · postmenopausal women and men with osteoporosis
1 g—1 year—
Changes in vitamin D metabolites during teriparatide treatment
2012 · placebo group · postmenopausal women and men with osteoporosis
1 g—1 year—
The necessity and safety of calcium and vitamin D in the elderly
1990 · Treatment group, independently living elderly women · Independently living elderly women
1.56 g45 mcg11 weeks—
The necessity and safety of calcium and vitamin D in the elderly
1990 · Treatment group, institutionalized elderly women · Institutionalized elderly women
1.56 g45 mcg11 weeks—
Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial
2014 · CaD · Children aged approximately 8 years
700 mg200 IU12 weeks—
Calcium-vitamin D-fortified milk is as effective on circulating bone biomarkers as fortified juice and supplement but has less acceptance: a randomised controlled school-based trial
2014 · supplement · Children aged 9–12 years, both sexes, in Tehran
500 mg200 IU12 weeks—
How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women
2016 · 100 000 IU vitamin D3 group (group 1D) · Women aged about 75 years receiving intermittent vitamin D therapy
1 g—1 year—
How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women
2016 · 200 000 IU vitamin D3 group (2D) · Women aged about 75 years receiving intermittent vitamin D therapy
1 g—1 year—
Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training
2017 · calcium and vitamin D · Young adults undergoing Army or Air Force initial military training
2 g1,000 IU9 weeks—
A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia
2017 · Initial daily Vitamin D3 + calcium citrate formulation · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency
1 g2,000 IU——
A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia
2017 · DOT Vitamin D3 intervention · Adolescents aged 10–21 years with newly diagnosed B-ALL or T-ALL and Vitamin D insufficiency or deficiency
800 mg—204 days—
Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation
2017 · VitD/Ca arm · HIV-infected, ART-naive participants with 25-(OH)D ≥10 and <75 ng/mL, CrCl ≥60 mL/min, and serum calcium <10.5 mg/dL; age and sex not specified
1 g4,000 IU48 weeks—
Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: A prospective, randomized, open-label, pilot study
2018 · arm A · Chinese adults with ulcerative colitis or Crohn's disease and vitamin D insufficiency or deficiency
600 mg—1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D3 2,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
500 mg2,000 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D3 3,000 IU daily · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
500 mg3,000 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D2 50,000 IU weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
500 mg7,143 IU1 year—
A PROSPECTIVE STUDY OF COMMONLY UTILIZED REGIMENS OF VITAMIN D REPLACEMENT AND MAINTENANCE THERAPY IN ADULTS
2019 · D2 50,000 IU twice weekly · Adults aged 25–85 years with 25(OH)D below 30 ng/mL
500 mg7,143 IU1 year—
Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults
2019 · Vitamin D3 group · Adults aged 60–80 with low serum 25(OH)D, clinically relevant depressive symptoms, and at least one functional limitation
500 mg1,200 IU26 weeks—
Calcium and vitamin D supplementation and bone health in Marine recruits: Effect of season
2019 · Ca + D fortified snack bars · Male and female Marine recruits, mean age 18.9 years, undergoing 12 weeks of initial military training
2 g1,000 IU12 weeks—
Vitamin D-A Risk Factor for Bone Fractures in Children: A Population-Based Prospective Case-Control Randomized Cross-Sectional Study
2023 · study group · Children aged 2–17 years with fractures; supplementation was given when serum 25-OH-vitamin D was below 30 ng/mL.
600 mg2,000 IU26 weeks—
High-dose cholecalciferol supplementation to obese infertile men is sufficient to reach adequate vitamin D status
2024 · active group · Infertile men, including men with normal weight, overweight, and obesity
500 mg301 g150 days—
Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D
1998 · Vit D3 group · Postmenopausal women
500 mg—1 year—
Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D
1998 · HRT + Vit D3 group · Postmenopausal women
500 mg—1 year—
Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial
2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception
150 mg10 mcg—870
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis
2010 · Placebo group · Postmenopausal women with osteoporosis and prevalent fractures
1 g—548 days544
Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis
2010 · Teriparatide 20 μg group · Postmenopausal women with osteoporosis and prevalent fractures
1 g—548 days541
Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men
2022 · Vitamin D and calcium group · Infertile men; age not stated
500 mg1,400 IU150 days151
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism
2020 · high dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml
1 g3,750 IU1 year129
Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism
2020 · low dose vitamin D3 arm · Adults aged 65 years or older, overweight, ambulatory, with serum 25(OH)D of 10–30 ng/ml
1 g600 IU1 year128
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
2007 · PTH group · Postmenopausal women with low bone mineral density and osteoporosis
500 mg400 IU1 year119
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy
2005 · Group B · Patients after total thyroidectomy
1.5 g2 mcg—111
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy
2005 · Group A · Patients after total thyroidectomy
1.5 g1 mcg—104
Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study
2005 · calcium + vitamin D group · Ambulatory women older than 65 years with vitamin D insufficiency (25-hydroxyvitamin D level ≤12 ng/mL)
1 g—1 year95
A Combined Nutrition and Exercise Intervention Influences Serum Vitamin B-12 and 25-Hydroxyvitamin D and Bone Turnover of Healthy Chinese Middle-Aged and Older Adults
2020 · intervention group · Chinese men and women aged 50 years or older, apparently healthy and community-dwelling
1.01 g30 mcg24 weeks80
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover
2004 · Calcitonin group · Women older than 65 with high bone turnover, at high risk of osteoporosis
500 mg200 IU26 weeks75
Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study
2013 · D+ group · Adults with primary hyperparathyroidism after parathyroidectomy
1 g1,600 IU1 year75
Consumption of a calcium and vitamin D-fortified food product does not affect iron status during initial military training: a randomised, double-blind, placebo-controlled trial
2016 · Ca/vitamin D group · Young adult male and female volunteers enrolled in US Army basic combat training
2 g25 mcg9 weeks75
Effects of vitamin D supplementation on salivary immune responses during Marine Corps basic training
2019 · Vitamin D3 + calcium group · Male and female US Marine Corps recruits entering basic training; ages and vitamin D status not specified
2 g1,000 IU12 weeks73
Impact of vitamin D supplementation during lactation on vitamin D status and body composition of mother-infant pairs: a MAVID randomized controlled trial
2014 · 1200 IU/d group · Caucasian lactating mothers who delivered a healthy term infant and intended to breastfeed for 6 months
200 mg800 IU26 weeks70
Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial
2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years
500 mg125 IU1 year68
Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial
2003 · high dose · Postmenopausal Chinese women aged 48–62 years
500 mg125 IU1 year68
Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study
2011 · calcium carbonate (control group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck
1 g—3 years65
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis
2007 · PTH/alendronate combination group · Postmenopausal women with low bone mineral density and osteoporosis
500 mg400 IU1 year59
Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study
2011 · OHC (treatment group) · Women aged over 65 years with densitometric osteoporosis of the lumbar spine or femoral neck
1.66 g—3 years55
Bioavailability of calcium: comparison of calcium carbonate and milk and the effect of vitamin D, age, and sex using 24-hour urine calcium as a method
2005 · CaCO(3) + cholecalciferol · Healthy younger women and older women and men; median ages 30 and 66, respectively
1.2 g1,200 IU4 weeks53
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · ALN add TPTD · Postmenopausal women with osteoporosis previously treated with alendronate
500 mg400 IU26 weeks52
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · ALN switch TPTD · Postmenopausal women with osteoporosis previously treated with alendronate
500 mg400 IU26 weeks50
Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial
2017 · Vitamin D3-fortified doogh (FD) · Adults with type 2 diabetes; age and sex not specified
340 mg1,000 IU12 weeks50
Once daily calcium (1000 mg) and vitamin D (1000 IU) supplementation during military training prevents increases in biochemical markers of bone resorption but does not affect tibial microarchitecture in Army recruits
2022 · Ca + D fortified food bar · Male and female Army recruits undergoing basic combat training; mean age 21.8 years
1 g1,000 IU8 weeks50
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · RLX switch TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene
500 mg400 IU26 weeks49
Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate
2003 · Calcitriol pulse therapy (crossover) with calcium carbonate · Adults with chronic hemodialysis; age and sex not reported
4.5 g—26 weeks48
Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
2004 · Control group · Postmenopausal women aged 45–65 with active rheumatoid arthritis
500 mg400 IU2 years47
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
2008 · RLX add TPTD · Postmenopausal women with osteoporosis previously treated with raloxifene
500 mg400 IU26 weeks47
Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission
500 mg10 mcg1 year43
Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
2004 · HRT group · Postmenopausal women aged 45–65 with active rheumatoid arthritis
500 mg400 IU2 years41
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study
2009 · Group 1 · Postmenopausal women with osteoporosis
1 g400 IU1 year41
Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D
2014 · VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 23.0 years
600 mg400 IU1 year41
The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes
2014 · vitamin D group · Adults aged 30–69 with vitamin D-deficient type 2 diabetes
200 mg2,000 IU24 weeks40
Changes in biochemical indices of bone metabolism in post-menopausal women following a dietary intervention with fortified dairy products
2009 · dairy intervention group (IG) · Post-menopausal women
1.2 g7.5 mcg150 days39
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
2011 · First group · Postmenopausal women with osteoporosis
600 mg400 IU26 weeks37
Effect of vitamin D, calcium and multiple micronutrients supplementation on lipid profile in pre-menopausal Bangladeshi garment factory workers with hypovitaminosis D
2014 · MMN-VD-Ca group · Young pre-menopausal female garment factory workers with hypovitaminosis D; ages reported as group mean 22.4 years
600 mg400 IU1 year37
Consumption of vitamin D-and calcium-fortified soft white cheese lowers the biochemical marker of bone resorption TRAP 5b in postmenopausal women at moderate risk of osteoporosis fracture
2012 · treated · Healthy postmenopausal women aged 56.6 ± 3.9 years with low spontaneous calcium and vitamin D intake
400 mg2.5 mcg6 weeks36
Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial
2021 · group B · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet
500 mg250 IU6 weeks36
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin
2011 · Second group · Postmenopausal women with osteoporosis
600 mg400 IU26 weeks34
Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China
2020 · low VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D <10 ng/mL
600 mg0.25 mcg26 weeks34
Role of vitamin D-calcium supplementation on metabolic profile and oxidative stress in gestational diabetes mellitus: A randomized controlled trial
2021 · group A · Women diagnosed with gestational diabetes mellitus at 24–28 weeks of gestation, controlled on a diabetic diet
1 g1,000 IU6 weeks34
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 3 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
1 g20 mcg1 year33
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 6 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
1 g20 mcg1 year33
Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial
2008 · ch-OSA 12 mg Si · Mostly postmenopausal women, mean age about 60, with osteopenia and otherwise healthy
1 g20 mcg1 year33
The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD
2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified
1 g10 mcg12 weeks33
Between-meal risedronate does not alter bone turnover in nursing home residents
2006 · Risedronate group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline
630 mg400 IU12 weeks31
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/HK · Postmenopausal women aged 50–65 years
1 g16.3 mcg12 weeks31
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/LK · Postmenopausal women aged 50–65 years
1 g15 mcg12 weeks31
Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers
2018 · D + Ca · Adults, mean age 68.4 years; no specific condition stated
800 mg—1 year31
A pilot intervention to increase calcium intake in female collegiate athletes
2004 · treatment group · Female collegiate athletes with regular menstrual cycles; age not reported
1 g400 IU16 weeks30
Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D
2014 · vitamin D-fortified doogh (DD) · Adults aged 30–50 of both sexes with type 2 diabetes
300 mg1,000 IU12 weeks30
Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D
2014 · calcium-vitamin D-fortified doogh (CDD) · Adults aged 30–50 of both sexes with type 2 diabetes
500 mg1,000 IU12 weeks30
Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial
2014 · calcium-vitamin D group · Adults aged over 30 with type 2 diabetes and insufficient 25-hydroxyvitamin D
1 g—8 weeks30
The effects of vitamin D plus calcium supplementation on metabolic profiles, biomarkers of inflammation, oxidative stress and pregnancy outcomes in pregnant women at risk for pre-eclampsia
2016 · vitamin D3 plus calcium · Pregnant women at risk for pre-eclampsia, from 20 to 32 weeks of gestation
1 g—12 weeks30
The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome
1 g400 IU8 weeks30
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · LD/HK · Postmenopausal women aged 50–65 years
1 g3.86 mcg12 weeks30
Between-meal risedronate does not alter bone turnover in nursing home residents
2006 · Placebo group · Skilled nursing-home residents, mean age 76 years; 46 men and 14 women overall, with hypovitaminosis D common at baseline
630 mg400 IU12 weeks29
Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women
2013 · vitamin D- and calcium-fortified yogurt (FY) · Institutionalized women, mean age 85.5 years, at high risk for vitamin D deficiency and osteoporotic fracture
800 mg10 mcg8 weeks29
Effects of calcium-vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial
2014 · calcium-vitamin D group · Pregnant women aged 18–40 years with gestational diabetes at 24–28 weeks' gestation
1 g—6 weeks28
The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome
2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome
1 g400 IU8 weeks28
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 600 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
500 mg600 IU16 weeks28
Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins
2017 · vitamin D arm · Participants; age, sex, and health condition not specified
800 mg1,200 IU1 year27
Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia
2020 · Group B (control) · Postmenopausal women with osteopenia
1.25 g400 IU90 days27
Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial
2015 · Group C · Overweight, vitamin D-deficient women aged 18–40 years with PCOS
1 g7,143 IU8 weeks26
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 1200 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
500 mg1,200 IU16 weeks26
Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial
2022 · 4000 IU vitamin D3 + 500 mg calcium · Women aged 20–45 years in Malaysia; vitamin D status varied, with most participants below 50 nmol/L at baseline.
500 mg4,000 IU16 weeks26
Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women
2000 · calcium carbonate plus calcitriol · Thai postmenopausal women with osteoporosis, more than 10 years postmenopausal
750 mg0.5 mcg90 days25
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
2010 · Treatment group · Patients with multiple sclerosis; age and sex not specified
1.2 g40,000 IU52 weeks25
Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis
2011 · treated patients · Patients with multiple sclerosis; age and sex ranges not reported
1.2 g—1 year25
Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China
2020 · high VitD experimental group · Postmenopausal women with osteoporosis and serum 25(OH)D ≥10 ng/mL
600 mg0.25 mcg26 weeks25
The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes
2021 · Ca+D-yogurt drink (CDY) · Adults aged 30–60 years with confirmed type 2 diabetes
500 mg1,000 IU12 weeks25
Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial
2012 · calcium-vitamin D supplements · Pregnant women aged 18–35 in the third trimester, primigravida, with singleton pregnancies and at risk for pre-eclampsia
500 mg200 IU9 weeks24
Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia
2020 · Group A · Postmenopausal women with osteopenia
3.6 g400 IU90 days24
Alfacalcidol (alpha D3) and calcium in osteoporosis
1994 · treatment group · Postmenopausal women with osteoporosis; mean age 67 years
1 g0.5 mcg3 years24
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover
2004 · Calcium and vitamin D control group · Women older than 65 with high bone turnover, at high risk of osteoporosis
500 mg200 IU26 weeks23
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis
2004 · No-alendronate group (controls) · HIV-infected men and women on stable HAART with osteopenia or osteoporosis
1 g500 IU52 weeks23
Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial
2009 · 2.0 g elemental calcium plus 800 IU vitamin D3 · Adults aged 30–75 in generally good health with at least one pathology-confirmed sporadic colon or rectal adenoma in the previous 36 months
2 g800 IU26 weeks23
Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial
2009 · calcium plus vitamin D supplementation group · Adults aged 30–75 in general good health with a history of at least one pathology-confirmed colorectal adenoma within the past 36 months
2 g800 IU26 weeks23
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients
2010 · calcium plus vitamin D3 supplementation group · Adults aged 30–75 with a history of at least one adenomatous colonic or rectal polyp within the past 36 months
2 g800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients
2011 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp in the preceding 36 months
2 g800 IU180 days23
Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial
2011 · 2.0 g elemental calcium plus 800 IU vitamin D3 group · Adults aged 30–75 with a history of sporadic colorectal adenoma
2 g800 IU26 weeks23
A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients
2012 · 2.0 g elemental calcium plus 800 IU vitamin D3 supplementation · Adults aged 30–75 with a history of at least one pathology-confirmed adenomatous colorectal polyp within the past 36 months
2 g800 IU26 weeks23
Effects of calcium and vitamin D3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: a randomized controlled trial
2015 · calcium plus vitamin D3 group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp within the past 36 months; both sexes
2 g800 IU26 weeks23
Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture
2011 · Soft plain cheese consumption period · Institutionalized women aged 65 years or older with vitamin D insufficiency and low calcium intake
302 mg2.5 mcg6 weeks21
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study
2009 · Group 2 (control group) · Postmenopausal women with osteoporosis
1 g400 IU1 year20
Calcium and vitamin-D supplementation on bone structural properties in peripubertal female identical twins: a randomised controlled trial
2011 · calcium-supplemented group · Peripubertal girls aged 9 to 13 years
800 mg400 IU26 weeks20
Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study
2018 · K citrate group · Postmenopausal women with osteopenia, more than 5 years post-menopause
500 mg400 IU26 weeks20
Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study
2018 · Placebo group with background supplements · Postmenopausal women with osteopenia, more than 5 years post-menopause
500 mg400 IU26 weeks20
Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D
1996 · three tablets containing 1000 mg CaCO3 plus 5 micrograms (200 IU) vitamin D/d · Healthy women aged 28–59 years
1 g5 mcg3 days20
Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation
2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase
1 g4,000 IU6 weeks19
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis
2004 · Alendronate-treatment group · HIV-infected men and women on stable HAART with osteopenia or osteoporosis
1 g500 IU52 weeks18
Effects of supplemental vitamin D and calcium on markers of proliferation, differentiation, and apoptosis in the normal colorectal mucosa of colorectal adenoma patients
2018 · Calcium + Vitamin D (4-arm randomization) · Adults aged 45–75 with a removed histologically verified colorectal adenoma; men and women
1.2 g1,000 IU1 year17
Temporal Change in Biomarkers of Bone Turnover Following Late Evening Ingestion of a Calcium-Fortified, Milk-Based Protein Matrix in Postmenopausal Women with Osteopenia
2019 · milk-based protein matrix (MBPM) · Postmenopausal women aged 50–70 with osteopenia
875 mg—1 day16
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women
2008 · calcium and vitamin D group · Postmenopausal women with osteoporosis
1 g—90 days13
Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome
2006 · supplementation group · Adults with Down's syndrome living in an institution
1 g800 IU1 year12
[Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3]
1995 · 1-alpha(OH) vitamin D3 group · Postmenopausal women with osteoporosis
500 mg0.5 mcg26 weeks12
Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa
2006 · calcium plus vitamin D treatment group · Adults with adenomatous polyps; age and sex not stated
4.5 g400 IU26 weeks11
Systemic vitamin D supplementation and local bone formation after maxillary sinus augmentation - a randomized, double-blind, placebo-controlled clinical investigation
2016 · vitamin D3 + calcium group · Adults undergoing maxillary sinus augmentation; age and sex not stated
600 mg5,000 IU213 days10
SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
2015 · Calcium citrate group (Group 1 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–55
1.2 g800 IU60 days10
SECONDARY HYPERPARATHYROIDISM AFTER BARIATRIC SURGERY: TREATMENT IS WITH CALCIUM CARBONATE OR CALCIUM CITRATE?
2015 · Calcium carbonate group (Group 2 in Methods) · Adults who underwent Roux-en-Y gastric bypass and had mainly abnormal alkaline phosphatase, vitamin D and PTH levels; ages 25–68
1.2 g800 IU60 days10
Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
1994 · intravenous group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported
2.5 g—36 weeks10
Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
1994 · pulse oral group · Hemodialysis patients with end-stage renal disease and severe hyperparathyroidism; age and sex not reported
2.5 g—36 weeks9
A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis
1993 · Study group: 2.5 mEq/L calcium dialysate with oral calcitriol · Patients on peritoneal dialysis
900 mg0.25 mcg8 weeks9
Tibial bone responses to 6-month calcium and vitamin D supplementation in young male jockeys: A randomised controlled trial
2015 · Supplemented group · Apprentice male jockeys, mean age 20.2 ± 3.2 years, engaged in caloric restriction and high volumes of physical activity
800 mg400 IU26 weeks8
The effect of calcium and vitamin D supplementation on bone health of male Jockeys
2017 · calcium and vitamin D group · Apprentice male jockeys; mean age 20.18 ± 3.23 years
800 mg400 IU26 weeks8
Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion
2001 · Two doses of Orocal D3 at a 6-hour interval · Healthy male volunteers; age not stated
1 g800 IU1 day—
Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion
2001 · One morning dose of Cacit vitamin D3 · Healthy male volunteers; age not stated
1 g880 IU1 day—
Alendronate prevents further bone loss in renal transplant recipients
2001 · Group A · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier
500 mg0.5 mcg1 year—
Alendronate prevents further bone loss in renal transplant recipients
2001 · Group B · Adults aged 44.2 ± 11.6 years with a kidney transplant at least 6 months earlier
500 mg0.5 mcg1 year—
Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
2002 · Two doses of Orocal D3 · Healthy volunteers; age and sex not specified
1 g800 IU1 day—
Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
2002 · Single morning dose of Cacit D3 · Healthy volunteers; age and sex not specified
1 g880 IU1 day—
Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels
2002 · calcium-vitamin D (CaD) group · postmenopausal women with serum 25(OH)vitamin D levels below 18 ng/mL
500 mg200 IU90 days—
Comparisons of oral calcium, high dose vitamin D and a combination of these in the treatment of nutritional rickets in children
2002 · Vitamin D plus calcium group · Infants aged 6–30 months with nutritional rickets
3 g—4 weeks—
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women
2004 · calcium citrate · Older postmenopausal women
1 g900 IU12 weeks—
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women
2004 · calcium carbonate · Older postmenopausal women
1 g900 IU12 weeks—
Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women
2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine
563 mg0.6 mcg8 weeks—
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
2004 · placebo · Postmenopausal women with osteoporosis
500 mg—3 years—
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
2004 · raloxifene 60 mg/day · Postmenopausal women with osteoporosis
500 mg—3 years—
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
2004 · raloxifene 120 mg/day · Postmenopausal women with osteoporosis
500 mg—3 years—
Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial
2005 · group A · Postmenopausal women aged 49–71 years; healthy
1.2 g5.7 mcg26 weeks—
Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial
2005 · group B · Postmenopausal women aged 49–71 years; healthy
900 mg5.7 mcg26 weeks—
Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake
2005 · High-calcium mineral water plus vitamin D · Postmenopausal women with dietary calcium intake below 700 mg/day; mean age 70.1 years
596 mg400 IU26 weeks—
Dietary acid-base balance, bone resorption, and calcium excretion
2006 · Cereal (acidogenic) diet group · Healthy older men and women
600 mg400 IU60 days—
Dietary acid-base balance, bone resorption, and calcium excretion
2006 · Fruit and vegetable (alkalinogenic) diet group · Healthy older men and women
600 mg400 IU60 days—
Effect of calcium, vitamins K1 and D3 on bone in galactosemia
2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia
750 mg10 mcg2 years—
The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults
2007 · calcium and vitamin D supplementation · Caucasian adults aged 65 years or older without diabetes; baseline fasting glucose was normal or impaired
500 mg700 IU3 years—
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
2007 · Placebo · Adults with osteoporosis or low bone mass: postmenopausal women and men
1 g—1 year—
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
2007 · TPTD 20 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men
1 g—1 year—
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
2007 · TPTD 40 microg/d · Adults with osteoporosis or low bone mass: postmenopausal women and men
1 g—1 year—
Biochemical short-term changes produced by hormonal replacement therapy
1991 · calcium · White postmenopausal women, 6 months to 6 years after menopause
1.7 g400 IU60 days—
Biochemical short-term changes produced by hormonal replacement therapy
1991 · cyclic estrogen-progestin plus calcium · White postmenopausal women, 6 months to 6 years after menopause
1.7 g400 IU60 days—
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss
2008 · Placebo group · Postmenopausal Korean women aged 50–65 with moderate bone loss
600 mg400 IU12 weeks—
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss
2008 · Alendronate group · Postmenopausal Korean women aged 50–65 with moderate bone loss
600 mg400 IU12 weeks—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · placebo · Men and women aged 50 and older; described as healthy older adults
600 mg525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults
600 mg525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · sodium bicarbonate group · Men and women aged 50 and older; described as healthy older adults
600 mg525 IU90 days—
Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women
2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults
600 mg525 IU90 days—
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD
2009 · calcium-vitamin D(3) fixed combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease
1.2 g800 IU26 weeks—
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD
2009 · calcium plus vitamin D(3) separate combination · Elderly white women; the analysis focused on participants with moderate chronic kidney disease
1.2 g800 IU26 weeks—
Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial
2010 · calcium plus vitamin D supplementation group · Adults aged 30–75 with a history of at least one adenomatous colorectal polyp
2 g800 IU26 weeks—
Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D
2010 · group 1 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L
1 g1,000 IU8 weeks—
Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D
2010 · group 2 · postmenopausal volunteers with initial serum 25OHD below 60 nmol/L
1 g1,000 IU8 weeks—
The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design
2010 · vitamin D3 and calcium · Healthy men and women aged 20–80 years
1.2 g100 mcg90 days—
Vitamin D supplementation and bone mass accrual in underprivileged adolescent Indian girls
2010 · Ergocalciferol intervention group · Post-menarcheal underprivileged girls aged 14–15 years in Pune, India
250 mg———
Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial
2011 · vitamin D-fortified yogurt drink (DY) · people with type 2 diabetes; age and sex not stated
300 mg1,000 IU12 weeks—
Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial
2011 · vitamin D + calcium-fortified yogurt drink (DCY) · people with type 2 diabetes; age and sex not stated
500 mg1,000 IU12 weeks—
Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness
2012 · ibandronate group · Postmenopausal women with chronic critical illness
1.25 g0.25 mcg11 days—
Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness
2012 · placebo group · Postmenopausal women with chronic critical illness
1.25 g0.25 mcg11 days—
Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial
2011 · PRT + fortified milk supplement · Healthy men aged 50–79 years
1 g800 IU548 days—
Inflammatory cytokine responses to progressive resistance training and supplementation with fortified milk in men aged 50+ years: an 18-month randomized controlled trial
2011 · Fortified milk supplement · Healthy men aged 50–79 years
1 g800 IU548 days—
[Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes]
2011 · group II · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis
440 mg100 IU1 year—
Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes
2012 · vitamin D-fortified doogh (DD) · Adults aged 30–60 of both sexes with type 2 diabetes
300 mg1,000 IU12 weeks—
Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes
2012 · calcium + vitamin D3-fortified doogh (CDD) · Adults aged 30–60 of both sexes with type 2 diabetes
500 mg1,000 IU12 weeks—
Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone
2012 · alfacalcidol group · Children receiving long-term glucocorticoids
400 mg—1 year—
Management of nutritional rickets in Indian children: a randomized controlled trial
2013 · combination therapy · Children aged 6 months to 5 years with nutritional rickets
75 mg/kg—12 weeks—
One year B and D vitamins supplementation improves metabolic bone markers
2013 · group B · Healthy adults older than 54 years
456 mg1,200 IU1 year—
Enhanced effect of zinc and calcium supplementation on bone status in growth hormone-deficient children treated with growth hormone: a pilot randomized controlled trial
2013 · Group A · Prepubertal children with growth hormone deficiency, mean age 8.7 ± 2.8 years; 18 boys across the study
500 mg—1 year—
Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial
2013 · vitamin D-fortified doogh (DD) · Men and women aged 30–60 years with type 2 diabetes
300 mg1,000 IU12 weeks—
Regular consumption of both vitamin D- and calcium- and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial
2013 · calcium- and vitamin D-fortified doogh (CDD) · Men and women aged 30–60 years with type 2 diabetes
500 mg1,000 IU12 weeks—
Calcium and vitamin d supplementation in postmenopausal women
2013 · vitamin D3 and calcium · healthy postmenopausal white women
1.2 g100 mcg26 weeks—
Multinutrient-fortified juices improve vitamin D and vitamin E status in children: a randomized controlled trial
2014 · CaDEA · Children aged approximately 8 years
700 mg200 IU12 weeks—
Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study
2014 · intervention group (IG) · Steroid-naïve pre-pubertal children with new-onset nephrotic syndrome treated with glucocorticoids; boys and girls
500 mg1,000 IU12 weeks—
Effect of supplemental vitamin D and calcium on serum sclerostin levels
2014 · vitamin D and calcium group · Men and women aged 65 years and older, described as healthy
500 mg—2 years—
Calcium and vitamin D supplementation maintains parathyroid hormone and improves bone density during initial military training: a randomized, double-blind, placebo controlled trial
2014 · Ca+Vit D · Men and women undergoing Army initial military training (basic combat training); ages and health conditions not specified
2 g1,000 IU9 weeks—
Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial
2014 · joint calcium-vitamin D group · Adults with vitamin D insufficiency and type 2 diabetes; age and sex range not stated
1 g7,143 IU8 weeks—
Calcium supplementation increases blood creatinine concentration in a randomized controlled trial
2014 · Calcium plus vitamin D · Adults aged 45–75 in generally good health with a previously removed large bowel adenoma; predominantly male
1.2 g1,000 IU5 years—
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density
2016 · Alendronate (ALN) arm · HIV-infected men and women aged 25 years or older with low bone mineral density
1 g—48 weeks—
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density
2016 · Placebo arm · HIV-infected men and women aged 25 years or older with low bone mineral density
1 g—48 weeks—
A Vitamin D-Calcium-Fortified Yogurt Drink Decreased Serum PTH but did not Affect Osteocalcin in Subjects with Type 2 Diabetes
2015 · Group 3 (CDD) · Women and men aged 30–50 years with type 2 diabetes
500 mg1,000 IU12 weeks—
Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients
2017 · 1,200 mg/day elemental calcium plus 1,000 IU/day vitamin D3 supplementation · Adults aged 45–75 with a history of colorectal adenomas
1.2 g1,000 IU1 year—
One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation
2017 · group B · Adults older than 54 years; no specific condition stated
456 mg1,200 IU1 year—
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial
2017 · Calcium + vitamin D alone · Postmenopausal women aged 50–79 in the WHI hormone therapy trials
1 g400 IU5 years—
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial
2017 · Calcium + vitamin D plus hormone therapy · Postmenopausal women aged 50–79 in the WHI hormone therapy trials
1 g400 IU5 years—
Effects of Vitamin D Supplementation on Semen Quality, Reproductive Hormones, and Live Birth Rate: A Randomized Clinical Trial
2018 · active group · Infertile men with serum 25-hydroxyvitamin-D levels ≤50 nmol/L
500 mg1,400 IU150 days—
Safety of calcium and vitamin D supplements, a randomized controlled trial
2018 · CaCO3 1200 mg/day with 10 000 IU vitamin D3/day · Healthy, white postmenopausal women
1.2 g10,000 IU1 year—
Safety of calcium and vitamin D supplements, a randomized controlled trial
2018 · CaCO3 1200 mg/day with 600 IU vitamin D3/day · Healthy, white postmenopausal women
1.2 g600 IU1 year—
Effects of vitamin D and calcium on expression of MSH2 and transforming growth factors in normal-appearing colorectal mucosa of sporadic colorectal adenoma patients: A randomized clinical trial
2019 · vitamin D3 plus calcium group · People with sporadic colorectal adenomas; age and sex not specified
1.2 g1,000 IU1 year—
Effects of supplemental calcium and vitamin D on tight-junction proteins and mucin-12 expression in the normal rectal mucosa of colorectal adenoma patients
2019 · calcium plus vitamin D supplementation · Adults aged 45–75 with a removed colorectal adenoma and no remaining polyps after colonoscopy; patients at increased risk for colorectal neoplasms
1.2 g1,000 IU1 year—
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial
2021 · calcium plus vitamin D group · Adults aged 45–75 with a histologically verified colorectal adenoma
1.2 g1,000 IU1 year—
Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial
2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy
800 mg38 mcg1 year—
Effect of Vitamin D and/or Calcium Supplementation on Pancreatic β-Cell Function in Subjects with Prediabetes: A Randomized, Controlled Trial
2023 · vitamin D plus calcium group · Chinese adults with prediabetes; the reported disposition-index result was for vitamin D-insufficient individuals
500 mg1,600 IU24 weeks—
Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3
1998 · cholecalciferol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism
1 g800 IU26 weeks—
Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3
1998 · calcitriol group · Inpatients with hypovitaminosis D and secondary hyperparathyroidism
500 mg—26 weeks—
Low dose estrogen and calcium have an additive effect on bone resorption in older women
1999 · Calcium plus vitamin D (Ca+D) · Healthy women over 70 years of age
1.5 g800 IU12 weeks—
Low dose estrogen and calcium have an additive effect on bone resorption in older women
1999 · Combination Ca+D and E2 · Healthy women over 70 years of age
1.5 g800 IU12 weeks—
Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults
2020 · One-serving WP-MND group during the open-label extension · Adults aged 65 years or older with sarcopenia who continued from the RCT
500 mg800 IU13 weeks133
Effect of adding B-vitamins to vitamin D and calcium supplementation on CpG methylation of epigenetic aging markers
2018 · D + Ca + B · Adults, mean age 68.4 years; no specific condition stated
800 mg—1 year32
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · Tablets · Postmenopausal women aged 50–65 years
2 g—12 weeks30
A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome
2017 · Magnesium-zinc-calcium-vitamin D co-supplementation · Women with polycystic ovary syndrome (PCOS)
800 mg400 IU12 weeks30
The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes
2019 · Magnesium-zinc-calcium-vitamin D group · Women aged 18–40 with gestational diabetes mellitus, at 24–28 weeks’ gestation at diagnosis
800 mg400 IU6 weeks30
Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins
2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified
800 mg1,200 IU1 year25
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 0.15 mg daily sCT · Healthy postmenopausal women aged 55–85 years
1 g400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 0.4 mg daily sCT · Healthy postmenopausal women aged 55–85 years
1 g400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 1.0 mg daily sCT · Healthy postmenopausal women aged 55–85 years
1 g400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 2.5 mg daily sCT · Healthy postmenopausal women aged 55–85 years
1 g400 IU90 days—
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover
2004 · 1.0 mg intermittent sCT (every other day) · Healthy postmenopausal women aged 55–85 years
1 g400 IU90 days—
One year B and D vitamins supplementation improves metabolic bone markers
2013 · group A · Healthy adults older than 54 years
456 mg1,200 IU1 year—
Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women
2016 · Intervention (Int), premenopausal women · Premenopausal women, mean age 41 years; no specific condition stated
1 g15 mcg12 weeks—
Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women
2016 · Intervention (Int), postmenopausal women · Postmenopausal women, mean age 59 years; no specific condition stated
1.2 g15 mcg12 weeks—
One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation
2017 · group A · Adults older than 54 years; no specific condition stated
456 mg1,200 IU1 year—
A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya
2017 · standard regimen · Pregnant women enrolled between 16 and 30 weeks of gestation
1.5 g200 IU8 weeks—
A Simplified Regimen Compared with WHO Guidelines Decreases Antenatal Calcium Supplement Intake for Prevention of Preeclampsia in a Cluster-Randomized Noninferiority Trial in Rural Kenya
2017 · low-dose regimen · Pregnant women enrolled between 16 and 30 weeks of gestation
1 g200 IU8 weeks—
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
2016 · placebo · Japanese adults aged 20–74 with rheumatoid arthritis on methotrexate
600 mg400 IU1 year88
Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
2025 · Randomized trial, placebo group · Infertile men; mean age approximately 34 years
400 mg25 mcg160 days49
Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial
2017 · placebo group · Postmenopausal women aged 50–72 years with osteopenia
500 mg200 IU26 weeks25
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial
2007 · Placebo group · Postmenopausal women with osteoporosis and low bone mineral density at the hip or lumbar spine
700 mg—548 days—
Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial
2014 · vitamin D3 and calcium carbonate · Healthy non-Hispanic white adults aged 45–75 years
1.2 g1,000 IU1 year—
Body mass index, calcium supplementation and risk of colorectal adenomas
2019 · VCPPS calcium carbonate plus vitamin D3 · People with a recently removed colorectal adenoma; sex and age range not specified
1.2 g1,000 IU1303 days—
Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides on Volumetric and Areal Bone Mineral Density, Bone Geometry and Bone Turnover in Postmenopausal Women With Osteopenia
2022 · Group B · Postmenopausal women with osteopenia
500 mg400 IU1 year—
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial
1998 · Control group · Postmenopausal women with osteoporosis, at least one prevalent vertebral fracture, and low bone mineral density; mean age 68.4 years
750 mg400 IU1 year—
Calcium and Vitamin D: study protocols | supp.fit